Patent
Modified human interferon polypeptides with at least one non-naturally encoded amino acid and their uses
| العنوان: | Modified human interferon polypeptides with at least one non-naturally encoded amino acid and their uses |
|---|---|
| Patent Number: | 8,097,702 |
| تاريخ النشر: | January 17, 2012 |
| Appl. No: | 11/875751 |
| Application Filed: | October 19, 2007 |
| مستخلص: | Modified interferon polypeptides with at least one non-naturally-encoded amino acid and uses thereof are provided. |
| Inventors: | Cho, Ho Sung (San Diego, CA, US); Daniel, Thomas O. (La Jolla, CA, US); Hays, Anna-Maria A. (San Diego, CA, US); Wilson, Troy E. (San Marino, CA, US) |
| Assignees: | Ambrx, Inc. (La Jolla, CA, US) |
| Claim: | 1. A variant of a human beta interferon (hIFNβ) polypeptide comprising a non-naturally encoded amino acid wherein said non-naturally encoded amino acid is substituted at position 107 and wherein the non-naturally encoded amino acid has the structure: [chemical expression included] and wherein the R group is any substituent other than one used in the twenty natural amino acids and wherein the hIFNβ variant further comprises one or more poly (ethylene glycol) moiety or moieties, at least one of said poly (ethylene glycol) moieties being coupled to the non-naturally encoded amino acid and wherein the resulting hIFNβ variant has a serum half-life at least two-fold greater than wild type hIFNβ. |
| Claim: | 2. The hIFNβ variant of claim 1 , wherein the non-naturally encoded amino acid is selectively reactive toward the one or more poly (ethylene glycol) moiety or moieties. |
| Claim: | 3. The hIFNβ variant of claim 1 , wherein the non-naturally encoded amino acid comprises a carbonyl group, an aminooxy group, a hydrazine group, a hydrazide group, a semicarbazide group, an azide group, or an alkyne group. |
| Claim: | 4. The hIFNβ variant of claim 1 , wherein the hIFNβ variant comprises one or more post-translational modifications. |
| Claim: | 5. The hIFNβ variant of claim 1 , wherein the hIFNβ variant is linked to a multifunctional polymer, bifunctional polymer, or at least one additional hIFNβ variant. |
| Claim: | 6. The hIFNβ variant of claim 1 , wherein the hIFNβ variant further comprises one or more free amide or free sulfhydryl groups. |
| Claim: | 7. The hIFNβ variant of claim 6 , wherein the free amide or free sulfhydryl groups are present in naturally occurring amino acids. |
| Claim: | 8. The hIFNβ variant of claim 1 , wherein the serum half-life of the hIFNβ variant is at least three-fold greater than wild type hIFNβ. |
| Claim: | 9. The hIFNβ variant of claim 8 , wherein the hIFNβ variant comprises a second non-naturally encoded amino acid. |
| Claim: | 10. The hIFNβ variant of claim 1 , wherein the hIFNβ variant is linked to a linker, polymer, or biologically active molecule. |
| Claim: | 11. The hIFNβ variant of claim 10 , wherein the linker or polymer is linked to a second polypeptide. |
| Claim: | 12. The hIFNβ variant of claim 11 , wherein the second polypeptide is a hIFNβ variant. |
| Current U.S. Class: | 530/351 |
| Patent References Cited: | 3773919 November 1973 Boswell et al. 4241174 December 1980 Familletti et al. 4289690 September 1981 Pestka et al. 4289872 September 1981 Denkewalter et al. 4364863 December 1982 Leibowitz et al. 4412989 November 1983 Iwashita et al. 4414148 November 1983 Jansen et al. 4414150 November 1983 Goeddel 4432895 February 1984 Tarnowski 4446235 May 1984 Seeburg 4456748 June 1984 Goeddel 4485045 November 1984 Regen 4511502 April 1985 Builder et al. 4511503 April 1985 Olson et al. 4512922 April 1985 Jones et al. 4514507 April 1985 Secher 4530901 July 1985 Weissmann 4544545 October 1985 Ryan et al. 4551433 November 1985 DeBoer 4569789 February 1986 Blattler et al. 4588585 May 1986 Mark et al. 4601980 July 1986 Goeddel et al. 4604284 August 1986 Kung et al. 4604359 August 1986 Goeddel et al. 4614651 September 1986 Jarvis, Jr. et al. 4619794 October 1986 Hauser 4622292 November 1986 Revel et al. 4634677 January 1987 Goeddel et al. 4658021 April 1987 Goeddel et al. 4659839 April 1987 Nicolotti et al. 4665180 May 1987 Oude Alink 4670393 June 1987 Seeburg 4670417 June 1987 Iwasaki et al. 4671958 June 1987 Rodwell et al. 4672108 June 1987 Kung et al. 4675282 June 1987 Pang 4678751 July 1987 Goeddel 4680338 July 1987 Sundoro 4686191 August 1987 Itoh et al. 4689406 August 1987 Banks et al. 4695623 September 1987 Stabinsky 4699784 October 1987 Shih et al. 4727138 February 1988 Goeddel et al. 4738921 April 1988 Belagaje et al. 4738931 April 1988 Sugano et al. 4755465 July 1988 Gray et al. 4762791 August 1988 Goeddel et al. 4769233 September 1988 Bell et al. 4780530 October 1988 Teraoka et al. 4810643 March 1989 Souza 4810645 March 1989 Goeddel et al. 4816566 March 1989 DeChiara et al. 4820638 April 1989 Swetly et al. 4837148 June 1989 Cregg 4859600 August 1989 Gray et al. 4876197 October 1989 Burke et al. 4880734 November 1989 Burke et al. 4892743 January 1990 Leibowitz et al. 4894330 January 1990 Hershenson et al. 4897471 January 1990 Stabinsky 4898830 February 1990 Goeddel et al. 4898931 February 1990 Itoh et al. 4902502 February 1990 Nitecki et al. 4904584 February 1990 Shaw 4908432 March 1990 Yip 4914033 April 1990 Bell et al. 4917888 April 1990 Katre et al. 4921699 May 1990 DeChiara et al. 4925793 May 1990 Goeddel et al. 4929554 May 1990 Goeddel et al. 4929555 May 1990 Cregg et al. 4959210 September 1990 Smiles et al. 4963495 October 1990 Chang et al. 4966843 October 1990 McCormick et al. 4970161 November 1990 Kakutani et al. 4973479 November 1990 Innis 4975276 December 1990 Innis 5004689 April 1991 Fiers et al. 5019382 May 1991 Cummins, Jr. 5021234 June 1991 Ehrenfeld 5066786 November 1991 Protasi et al. 5081022 January 1992 Sondermeyer et al. 5089398 February 1992 Rosenberg et al. 5096705 March 1992 Goeddel et al. 5098703 March 1992 Innis 5104653 April 1992 Michalevicz 5120832 June 1992 Goeddel et al. 5122614 June 1992 Zalipsky 5162601 November 1992 Slightom 5190751 March 1993 Trotta 5196191 March 1993 Jardieu 5196323 March 1993 Bodo et al. 5208019 May 1993 Hansson et al. 5218092 June 1993 Sasaki et al. 5219564 June 1993 Zalipsky et al. 5229490 July 1993 Tam 5231176 July 1993 Goeddel et al. 5231178 July 1993 Holtz et al. 5244655 September 1993 Viscomi et al. 5252714 October 1993 Harris et al. 5268169 December 1993 Brandely et al. 5278286 January 1994 Kung et al. 5281698 January 1994 Nitecki 5290686 March 1994 Kendal et al. 5324639 June 1994 Brierley et al. 5324844 June 1994 Zalipsky 5376567 December 1994 McCormick et al. 5378823 January 1995 Martal et al. 5382657 January 1995 Karasiewicz et al. 5391713 February 1995 Borg 5424199 June 1995 Goeddel et al. 5441734 August 1995 Reichert et al. 5446090 August 1995 Harris 5460811 October 1995 Goeddel et al. 5460956 October 1995 Reichert et al. 5468478 November 1995 Saifer et al. 5473034 December 1995 Yasui et al. 5476653 December 1995 Pitt et al. 5480640 January 1996 Morales et al. 5516515 May 1996 Vellucci et al. 5516657 May 1996 Murphy et al. 5516673 May 1996 Margel et al. 5532142 July 1996 Johnston et al. 5534617 July 1996 Cunningham et al. 5540923 July 1996 Ebbesen et al. 5541293 July 1996 Stabinsky 5541312 July 1996 Revel et al. 5545723 August 1996 Goelz et al. 5554513 September 1996 Revel et al. 5559213 September 1996 Hakimi et al. 5571709 November 1996 Devauchelle et al. 5578707 November 1996 Novick et al. 5580723 December 1996 Wells et al. 5582823 December 1996 Souza 5582824 December 1996 Goeddel et al. 5583023 December 1996 Cerutti et al. 5591974 January 1997 Troyer et al. 5593667 January 1997 Kung et al. 5594107 January 1997 Potter et al. 5595888 January 1997 Gray et al. 5602034 February 1997 Tekamp-Olson 5602232 February 1997 Reichert et al. 5605827 February 1997 Jackwood et al. 5612460 March 1997 Zalipsky 5624895 April 1997 Sobel 5629203 May 1997 Shuster 5629384 May 1997 Veronese et al. 5632988 May 1997 Ingram et al. 5643575 July 1997 Martinez et al. 5650234 July 1997 Dolence et al. 5661009 August 1997 Stabinsky 5672662 September 1997 Harris et al. 5674706 October 1997 Shuster 5688666 November 1997 Bass et al. 5705363 January 1998 Imakawa 5710027 January 1998 Hauptmann et al. 5711944 January 1998 Gilbert et al. RE35749 March 1998 Rosenberg et al. 5723125 March 1998 Chang et al. 5731169 March 1998 Mogensen et al. 5736625 April 1998 Callstrom et al. 5738845 April 1998 Imakawa 5738846 April 1998 Greenwald et al. 5739208 April 1998 Harris 5747646 May 1998 Hakimi et al. 5750373 May 1998 Garrard et al. 5753220 May 1998 Suzuki et al. 5762923 June 1998 Gross et al. 5762939 June 1998 Smith et al. 5766582 June 1998 Yuen et al. 5766864 June 1998 Uno et al. 5766885 June 1998 Carrington et al. 5770191 June 1998 Johnson et al. 5780021 July 1998 Sobel 5780027 July 1998 Maroun 5789551 August 1998 Pestka 5795745 August 1998 Goeddel et al. 5795779 August 1998 McCormick et al. 5808096 September 1998 Zalipsky 5814485 September 1998 Dorin et al. 5817307 October 1998 Cummins 5824300 October 1998 Cummins 5824778 October 1998 Ishikawa et al. 5824784 October 1998 Kinstler et al. 5830456 November 1998 Cummins 5830705 November 1998 Souza 5831062 November 1998 Taylor et al. 5834250 November 1998 Wells et al. 5834594 November 1998 Hakimi et al. 5834598 November 1998 Lowman et al. 5843733 December 1998 Estes 5846526 December 1998 Cummins 5849282 December 1998 Kawai et al. 5849535 December 1998 Cunningham et al. 5849860 December 1998 Hakimi et al. 5854026 December 1998 Cunningham et al. 5858368 January 1999 Smith et al. 5861258 January 1999 Mogensen et al. 5861279 January 1999 Zhang et al. 5863530 January 1999 Gillies et al. 5869293 February 1999 Pestka 5871986 February 1999 Boyce 5889151 March 1999 Mogensen et al. 5891676 April 1999 Estes 5900461 May 1999 Harris 5908621 June 1999 Glue et al. 5908626 June 1999 Chang et al. 5932462 August 1999 Harris et al. 5935566 August 1999 Yuen et al. 5939285 August 1999 Devauchelle et al. 5939286 August 1999 Johnson et al. 5951974 September 1999 Gilbert et al. 5955307 September 1999 Ohsuye et al. 5955346 September 1999 Wells et al. 5958402 September 1999 Bazer et al. 5962411 October 1999 Rosen et al. 5965393 October 1999 Hasnain et al. 5980884 November 1999 Blatt et al. 5980948 November 1999 Goedemoed et al. 5981709 November 1999 Greenwald et al. 5989868 November 1999 Harrison et al. 5990237 November 1999 Bentley et al. 6004548 December 1999 Souza 6004573 December 1999 Rathi et al. 6004931 December 1999 Cunningham et al. 6007805 December 1999 Foster et al. 6013253 January 2000 Martin et al. 6013433 January 2000 Pellett et al. 6013478 January 2000 Wells et al. 6017731 January 2000 Tekamp-Olson et al. 6022711 February 2000 Cunningham et al. 6036949 March 2000 Richards et al. 6036956 March 2000 Jacob et al. 6042822 March 2000 Gilbert et al. 6046034 April 2000 Waschutza et al. 6069133 May 2000 Chiou et al. 6083723 July 2000 Tekamp-Olson 6086869 July 2000 Uyama et al. 6096304 August 2000 McCutchen 6117423 September 2000 Berg 6120762 September 2000 Johnson et al. 6126944 October 2000 Pellett et al. 6129912 October 2000 Hortin et al. 6136563 October 2000 Cunningham et al. 6143523 November 2000 Cunningham et al. 6159712 December 2000 Lau 6168932 January 2001 Uckun et al. 6174996 January 2001 Johnson et al. 6177074 January 2001 Glue et al. 6180096 January 2001 Kline 6183985 February 2001 Shuster 6183987 February 2001 van de Wiel et al. 6200780 March 2001 Chen et al. 6201072 March 2001 Rathi et al. 6204022 March 2001 Johnson et al. 6207145 March 2001 Tovey 6214966 April 2001 Harris 6225060 May 2001 Clark et al. 6242218 June 2001 Treco et al. 6245528 June 2001 Chao 6250469 June 2001 Kline 6261805 July 2001 Wood RE37343 August 2001 Tekamp-Olson 6270756 August 2001 Ericsson 6281211 August 2001 Cai et al. 6299869 October 2001 Chen et al. 6300475 October 2001 Chen et al. 6306821 October 2001 Mikos et al. 6312923 November 2001 Tekamp-Olson 6323006 November 2001 Peregrino Ferreira et al. 6331525 December 2001 Chiou et al. 6337191 January 2002 Swartz et al. 6338846 January 2002 Kang et al. 6342216 January 2002 Fidler et al. 6350589 February 2002 Morris et al. 6361969 March 2002 Galeotti 6368825 April 2002 Chao 6372206 April 2002 Soos et al. 6372218 April 2002 Cummins 6379661 April 2002 Souza 6410697 June 2002 Berg 6420339 July 2002 Gegg et al. 6423685 July 2002 Drummond et al. 6428954 August 2002 Wells et al. 6433144 August 2002 Morris et al. 6436386 August 2002 Roberts et al. 6436391 August 2002 Foster et al. 6436674 August 2002 Honjo et al. 6451346 September 2002 Shah et al. 6451561 September 2002 Wells et al. 6461603 October 2002 Bentley et al. 6472512 October 2002 LaFleur et al. 6482613 November 2002 Goeddel et al. 6489144 December 2002 Lau 6514729 February 2003 Bentzien 6515100 February 2003 Harris 6521427 February 2003 Evans 6524570 February 2003 Glue et al. 6531122 March 2003 Pedersen et al. 6552167 April 2003 Rose 6566132 May 2003 Watt 6572853 June 2003 Schneider-Fresenius et al. 6586207 July 2003 Tirrell et al. 6602498 August 2003 Shen 6608183 August 2003 Cox, III 6610281 August 2003 Harris 6610830 August 2003 Goeddel et al. 6638500 October 2003 El-Tayar et al. 6646110 November 2003 Nissen et al. 6703225 March 2004 Kojima et al. 6716606 April 2004 Souza 6780613 August 2004 Wells et al. 6927042 August 2005 Schultz et al. 7045337 May 2006 Schultz et al. 7083970 August 2006 Schultz et al. 7138371 November 2006 DeFrees et al. 7270809 September 2007 Cox, III 7314613 January 2008 Patten et al. 2001/0021763 September 2001 Harris 2001/0044526 November 2001 Shen 2001/0056171 December 2001 Kozlowski 2002/0002250 January 2002 Bentley et al. 2002/0037949 March 2002 Harris et al. 2002/0040076 April 2002 Harris et al. 2002/0042097 April 2002 Tirrell et al. 2002/0052009 May 2002 Hornauer et al. 2002/0052430 May 2002 Harris et al. 2002/0055169 May 2002 Tekamp-Olson 2002/0072573 June 2002 Bentley et al. 2002/0081660 June 2002 Swartz et al. 2002/0082345 June 2002 Kozlowski et al. 2002/0086939 July 2002 Kozlowski 2002/0099133 July 2002 Kozlowski 2002/0156047 October 2002 Zhao 2003/0023023 January 2003 Harris et al. 2003/0082575 May 2003 Schultz et al. 2003/0105224 June 2003 Roberts et al. 2003/0105275 June 2003 Bentley et al. 2003/0108885 June 2003 Schultz et al. 2003/0114647 June 2003 Harris et al. 2003/0143596 July 2003 Bentley et al. 2003/0153003 August 2003 Wells et al. 2003/0158333 August 2003 Roberts et al. 2003/0162949 August 2003 Cox 2003/0220447 November 2003 Harris 2003/0228274 December 2003 Rose 2004/0001838 January 2004 Zhao et al. 2004/0013637 January 2004 Bentley et al. 2004/0115774 June 2004 Kochendoerfer et al. 2004/0198637 October 2004 Schultz et al. 2005/0009049 January 2005 Chin et al. 2005/0085619 April 2005 Wilson et al. 2005/0170404 August 2005 Cho et al. 2005/0220762 October 2005 Cho et al. 2003270341 March 2004 2003293668 June 2004 3218121 November 1983 036 676 September 1981 036 776 September 1981 0041313 December 1981 052 322 May 1982 058 481 August 1982 073 657 March 1983 0083069 July 1983 102 324 March 1984 121 775 October 1984 127 839 December 1984 133 988 March 1985 143 949 June 1985 154 316 September 1985 155 476 September 1985 164 556 December 1985 183 503 June 1986 188 256 July 1986 229 108 July 1987 244 234 November 1987 0260350 March 1988 267 851 May 1988 284 044 September 1988 324 274 July 1989 329 203 August 1989 340 986 November 1989 400 472 December 1990 402 378 December 1990 439 508 August 1991 480 480 April 1992 510 356 October 1992 0593868 April 1994 605 963 July 1994 732 403 September 1996 809 996 December 1997 921 131 June 1999 946 736 October 1999 1219636 July 2002 2429207 February 2006 2426521 November 2006 2426762 December 2006 83-118008 January 1985 WO 85/02624 June 1985 88/07082 September 1988 89/01037 February 1989 89/01038 February 1989 90/01556 February 1990 90/02186 March 1990 90/02566 March 1990 90/05785 May 1990 90/10078 September 1990 90/10277 September 1990 90/13540 November 1990 90/14428 November 1990 91/00357 January 1991 92/01801 February 1992 92/02628 February 1992 92/16555 October 1992 92/16619 October 1992 93/03173 February 1993 WO 93/04699 March 1993 93/15189 August 1993 93/21259 October 1993 94/04193 March 1994 94/09027 April 1994 94/14758 July 1994 94/15625 July 1994 94/17039 August 1994 94/18247 August 1994 94/28024 December 1994 95/00162 January 1995 95/06058 March 1995 95/11924 May 1995 95/13090 May 1995 95/13312 May 1995 95/20672 August 1995 WO 95/25170 September 1995 95/33490 December 1995 96/00080 January 1996 96/06161 February 1996 96/07670 March 1996 96/21469 July 1996 96/25496 August 1996 96/29400 September 1996 96/40791 December 1996 96/41813 December 1996 97/03106 January 1997 97/18832 May 1997 97/26332 July 1997 97/32607 September 1997 98/05363 February 1998 98/26080 June 1998 WO 98/27211 June 1998 98/32466 July 1998 98/37208 August 1998 98/41562 September 1998 98/48837 November 1998 WO 98/48840 November 1998 99/03887 January 1999 99/05297 February 1999 99/07862 February 1999 99/09193 February 1999 99/10515 March 1999 99/31257 June 1999 99/32134 July 1999 99/32139 July 1999 99/32140 July 1999 99/45130 September 1999 WO 99/48525 September 1999 99/51721 October 1999 WO 99/55377 November 1999 99/67291 December 1999 00/20032 April 2000 WO 00/23114 April 2000 WO 00/23472 April 2000 00/26354 May 2000 00/55345 September 2000 00/55353 September 2000 WO 00/69913 November 2000 01/05956 January 2001 01/27301 April 2001 WO 01/68827 September 2001 01/90390 November 2001 02/06305 January 2002 02/085923 October 2002 02/086075 October 2002 WO 03/016472 February 2003 03/101972 December 2003 WO 2004/005467 January 2004 2004/035605 April 2004 2004/035743 April 2004 2004/058946 July 2004 2004/094593 November 2004 WO 2004/094593 November 2004 2005/007624 January 2005 2005/007870 January 2005 2005/019415 March 2005 2005/035727 April 2005 2005/074524 August 2005 2005/074546 August 2005 2005/074650 August 2005 WO 2005/074524 August 2005 WO 2005/074546 August 2005 WO 2005/074650 August 2005 |
| Other References: | Dieters et al., “Adding Amino Acids with Novel Reactivity to the Genetic Code of Saccharomyces cerevisiae”, J. Am. Chem. Soc., Oct. 1, 2003, 125(39):11782-11783. cited by other E.A. Cornish, “Probing Protein Structure and Function with Expanded Genetic Code”, Angew. Chem. Int. Ed. Eng, 1995 34:621-633. cited by other Debinski, W et al. “A wide range of human cancers express interleukin 4 (IL4) receptors that can be targeted with chimeric toxin composed of IL4 and Pseudomonas exotoxin,” J Biol Chem. Jul. 5, 1993;268(19):14065-70. cited by other Deiters, A., et al., “Adding Amino Acids with Novel Reactivity to the Genetic Code of Saccharomyces cerevisiae,” J. Am. Chem. Soc. 2003; 125(39):11782-11783. cited by other Delgado, C et al., “The uses and properties of PEG-linked proteins,” Crit Rev Ther Drug Carrier Syst. 1992;9 (3-4):249-304. cited by other Dennis, MS et al., “Albumin binding as a general strategy for improving the pharmacokinetics of proteins,” J Biol Chem. Sep. 20, 2002;277(38):35035-43. Epub Jul. 15, 2002. cited by other Dolphin, CT et al., “Missense mutation in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour syndrome,” Nat Genet. Dec. 1997;17(4):491-4. cited by other Doring, V et al., “Enlarging the amino acid set of Escherichia coli by infiltration of the valine coding pathway,” Science. Apr. 20, 2001;292(5516):501-4. cited by other Dougherty, DA. “Unnatural amino acids as probes of protein structure and function,” Curr Opin Chem Biol. Dec. 2000;4(6):645-52. cited by other Duewel, H et al., “Incorporation of trifluoromethionine into a phage lysozyme: implications and a new marker for use in protein 19F NMR,” Biochemistry. Mar. 18, 1997;36(11):3404-16. cited by other Eghtedarzadeh MK & S Henikoff “Use of oligonucleotides to generate large deletions” Nucleic Acids Res. Jun. 25, 1986;14(12):5115. cited by other Elling L et MR Kula., “Immunoaffinity partitioning: synthesis and use of polyethylene glycol-oxirane for coupling to bovine serum albumin and monoclonal antibodies,” Biotechnol Appl Biochem. Jun. 1991;13(3):354-62. cited by other Elliott, S et al., “Yeast-derived recombinant human insulin-like growth factor I: production, purification, and structural characterization,” J Protein Chem. Feb. 1990;9(1):95-104. cited by other Ellman, J.A., Mendel, D., Anthony-Cahill, S., Noren, C.J., Schultz, P.G. “Biosynthetic method for introducing unnatural amino acids site-specifically into proteins,” Methods in Enz., 1992; 202:301-336. cited by other Ellman, JA, et al. “Site-specific incorporation of novel backbone structures into proteins,” Science. Jan. 10, 1992;255 (5041):197-200. cited by other England, P. M., et al., “Backbone mutations in transmembrane domains of a ligand-gated ion channel: implications for the mechanism of gating,” Cell. Jan. 8, 1999;96(1):89-98. cited by other Eppstein et al., “Biological Activity of Liposome-Encapsulated Murine Interferon is Mediated by a Cell Membrane Receptor,” Proc. Natl. Acad. Sci. U.S.A.(1985); 82: 3688-3692. cited by other Fieschko, JC et al., “Controlled expression and purification of human immune interferon from high-cell-density fermentations of Saccharomyces cerevisiae,” Biotech. Bioeng. (1987) 29(9):1113-21. cited by other Forster, AC et al., “Programming peptidomimetic syntheses by translating genetic codes designed de novo,” Proc Natl Acad Sci U S A. May 27, 2003;100(11):6353-7. Epub May 16, 2003. cited by other Frankel, A et al., “Encodamers: unnatural peptide oligomers encoded in RNA,” Chem Biol. Nov. 2003;10 (11):1043-50. cited by other Fraser, MJ et al., “Expression of eucaryotic genes in insect cell cultures,” In Vitro Cell. Dev. Biol. 1989; 25:225-235. cited by other Friedman, O.M. & R. Chatterrji. “Synthesis of Derivatives of Glutamine as Model Substrates for Anti-Tumor Agents,” J. Am. Chem. Soc. 1959; 81(14):3750-3752. cited by other Fritz HJ et al., “Oligonucleotide-directed construction of mutations: a gapped duplex DNA procedure without enzymatic reactions in vitro,” Nucleic Acids Res. Jul. 25, 1988;16(14B):6987-99. cited by other Fromm, M. et al., “Expression of Genes Transferred into Monocot and Dicot Plant Cells by Electroporation,” Proc. Natl. Acad. Sci. USA (1985) 82:5824-8. cited by other Furter, R. “Expansion of the genetic code: site-directed p-fluoro-phenylalanine incorporation in Escherichia coli,” Protein Sci. Feb. 1998;7(2):419-26. cited by other Gaertner, HF et al., “Construction of protein analogues by site-specific condensation of unprotected fragments,” Bioconjug Chem. May-Jun. 1992;3(3):262-8. cited by other Gaertner, HF et al., “Chemo-enzymic backbone engineering of proteins. Site-specific incorporation of synthetic peptides that mimic the 64-74 disulfide loop of granulocyte colony-stimulating factor,” J Biol Chem. Mar. 11, 1994;269 (10):7224-30. cited by other Gallivan, JP et al., “Site-specific incorporation of biotinylated amino acids to identify surface-exposed residues in integral membrane proteins,” Chem Biol. Oct. 1997;4(10):739-49. cited by other Gellissen, G et al., “Heterologous protein production in yeast,” Antonie Van Leeuwenhoek. Aug. 1992;62(1-2):79-93. cited by other Geoghegan, KF and JG Stroh, “Site-directed conjugation of nonpeptide groups to peptides and proteins via periodate oxidation of a 2-amino alcohol. Application to modification at N-terminal serine,” Bioconjug Chem. Mar.-Apr. 1992;3(2):138-46. cited by other Gillam, S. & M Smith, “Site-specific mutagenesis using synthetic oligodeoxyribonucleotide primers: I. Optimum conditions and minimum oligodeoxyribonucleotide length,” Gene 1979; 8(1):81-97. cited by other Gleeson, MA et al., “Transformation of the methylotrophic yeast hansenula polymorphica,” J. Gen. Microbiol. (1986) 132:3459-3465. cited by other Goeddel, DV, “Systems for heterologous gene expression,” Methods Enzymol. 1990;185:3-7. cited by other Goeddel, DV et al., “Synthesis of human fibroblast interferon by E. coli,” Nucleic Acids Res. Sep 25, 1980;8 (18):4057-74. cited by other Goodson RJ et NV Katre. “Site-directed pegylation of recombinant interleukin-2 at its glycosylation site,” Biotechnology (N Y). Apr. 1990;8(4):343-6. cited by other Graves, SW et al., “Expression, purification, and initial kinetic characterization of the large subunit of the human mitochondrial DNA polymerase,” Biochemistry. Apr. 28, 1998;37(17):6050-8. cited by other Griffin, BA et al., “Specific Covalent Labeling of Recombinant Protein Molecules Inside Live Cells,” Science (1998) 281:269-272. cited by other Grundström T et al., “Oligonucleotide-directed mutagenesis by microscale ‘shot-gun’ gene synthesis,” Nucleic Acids Res. May 10, 1985;13(9):3305-16. cited by other Guckian, KM and ET Kool, “Highly Precise Shape Mimicry by a Difluorotoluene Deoxynucleoside, a Replication-Competent Substitute for Thymidine,” Angew. Chem. Int. Ed. Engl (1998) 36(24):2825-8. cited by other Hamano-Takaku, F et al., “A mutant Escherichia coli tyrosyl-tRNA synthetase utilizes the unnatural amino acid azatyrosine more efficiently than tyrosine,” J Biol Chem. Dec. 22, 2000;275(51):40324-8. cited by other Hang, HC and CR Bertozzi, “Chemoselective approaches to glycoprotein assembly,” Acc Chem Res. Sep. 2001;34 (9):727-36. cited by other Harris, JM et al. “Synthesis and Characterization of Poly(ethylene Glycol) Derivatives,” J. Polym. Sci. Chem. Ed. 1984; 22:341-352. cited by other Harris, JM. “Laboratory Synthesis of Polyethylene Glycol Derivatives,” JMS-Rev. Macromol. Chem. Phys. 1985;C25 (3): 325-373. cited by other Hendrickson, WA et al., “Selenomethionyl proteins produced for analysis by multiwavelength anomalous diffraction (MAD): a vehicle for direct determination of three-dimensional structure,” EMBO J. May 1990;9(5):1665-72. cited by other Henikoff, S and JG Henikoff “Amino Acid Substitution Matrices from Protein Blocks,” Proc. Natl. Acad. Sci. USA 1992; 89:10915-9. cited by other Hess, B. et al., “Cooperation of glycolytic enzymes,” J. Adv. Enzyme Reg. (1969) 7:149-67. cited by other Hinnen, A et al., “Transformation of yeast,” Proc Natl Acad Sci U S A. Apr. 1978;75(4):1929-33. cited by other Hirao, I et al., “An unnatural base pair for incorporating amino acid analogues into proteins,” Nat Biotechnol. Feb. 2002;20(2):177-82. cited by other Hitzeman, RA et al., “Isolation and characterization of the yeast 3-phosphoglycerokinase gene (PGK) by an immunological screening technique,” J. Biol Chem. Dec. 25, 1980;255(24):12073-80. cited by other Hofmann, K., et H. Bohn. “Studies on polypeptides. XXXVI. The effect of pyrazole-imidazole replacements on the S-protein activating potency of an S-peptide fragment,” J. Am Chem, (1966); 88(24):5914-5919. cited by other Hohsaka, T et al., “Efficient Incorporation of Nonnatural Amino Acids with Large Aromatic Groups into Streptavidin in In Vitro Protein Synthesizing Systems,” J. Am. Chem. Soc. 1999; 121(1); 34-40. cited by other Hohsaka, T et al., “Incorporation of Two Different Nonnatural Amino Acids Independently into a Single Protein through Extension of the Genetic Code,” J. Am. Chem. Soc. 1999; 121(51):12194-12195. cited by other Abuchowski, A. et al. “Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates,” Cancer Biochem Biophys. Jun. 1984;7(2):175-86. cited by other Altschul, SF et al. “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucleic Acids Res. Sep. 1, 1997;25(17):3389-402. cited by other Altschul, SF et al. “Basic local alignment search tool,” J Mol Biol. Oct. 5, 1990;215(3):403-10. cited by other Amann, E et al., “Vectors bearing a hybrid trp-lac promoter useful for regulated expression of cloned genes in Escherichia coli,” Gene. Nov. 1983;25(2-3):167-78. cited by other Anderson, JC et al., “Exploring the limits of codon and anticodon size,” Chem Biol. Feb. 2002;9(2):237-44. cited by other Andresz, H et al. Abstract of “Chemische Synthese verzweigter Polysaccharide, 5; Kopplung von Oligosacchariden und Amylose an verschiedene Träger durch Hydrazonbindung,” Makromol. Chem. 1978;179:301 Abstract. cited by other Arnold, FH. “Protein engineering for unusual environments,” Curr Opin Biotechnol. Aug. 1993;4(4):450-5. cited by other Azoulay, M., et al. “Glutamine analogues as Potential Antimalarials,” Eur. J. Med. Chem. (1991); 26(2):201-5. cited by other Bain, JD, et al. “Biosynthetic site-specific incorporation of a non-natural amino acid into a polypeptide,” J. Am Chem Soc 1989;111(20):8013-8014. cited by other Ballance, DJ et al., “Transformation of Aspergillus nidulans by the orotidine-5′-phosphate decarboxylase gene of Neurospora crassa,” Biochem Biophys Res Commun. Apr. 15, 1983;112(1):284-9. cited by other Barany, F. et al., “Genetic disease detection and DNA amplification using cloned thermostable ligase,” Proc Nati Acad Sci U S A. Jan. 1, 1991;88(1):189-93. cited by other Barton, DHR et al., “Synthesis of Novel alpha-Amino-Acids and Derivatives Using Radical Chemistry: Synthesis of L- and D-alpha-Amino-Adipic Acids, L-alpha-aminopimelic Acid and Appropriate Unsaturated Derivatives,” Tetrahedron (1987) 43:4297-4308. cited by other Bass, S et al., “Mutant Trp repressors with new DNA-binding specificities,” Science (1988) 242:240-245. cited by other Batzer, MA et al., “Enhanced evolutionary PCR using oligonucleotides with inosine at the 3′-terminus,” Nucleic Acids Res. Sep. 25, 1991;19(18):5081. cited by other Beach, D et al., “Functionally homologous cell cycle control genes in budding and fission yeast,” Nature Dec. 1982; 300:706-709. cited by other Beauchamp, CO et al., “A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and alpha 2-macroglobulin,” Anal Biochem. May 1983;131(1):25-33. cited by other Bernstein, FC, et al. “The protein data bank: a computer-based archival file for macromolecular structures,” J. Mol. Biol. 1977; 112:535-542. cited by other Boissel, JP et al., “Erythropoietin structure-function relationships. Mutant proteins that test a model of tertiary structure,” J Biol Chem. Jul. 25, 1993;268(21):15983-93. cited by other Boles, JO et al. “Bio-incorporation of telluromethionine into buried residues of dihydrofolate reductase,” Nat Struct Biol. May 1994;1(5):283-4. cited by other Botstein, D et D Shortie, “Strategies and applications of in vitro mutagenesis,” Science. Sep. 20, 1985;229 (4719):1193-201. cited by other Brunner, J. “New photolabeling and crosslinking methods,” Annu Rev Biochem. 1993;62:483-514. cited by other Buchner, J. et al., “A method for increasing the yield of properly folded recombinant fusion proteins: Single-chain immunotoxins from renaturation of bacterial inclusion bodies,” Anal. Biochem. 1992; 205(2): 263-270. cited by other Bückmann et al. “Functionalization of Poly(ethylene glycol) and Monomethoxy-Poly(ethylene glycol),”Makromol. Chem. 1981;182:1379-84. cited by other Budisa, N et al. “High-level biosynthetic substitution of methionine in proteins by its analogs 2-aminohexanoic acid, selenomethionine, telluromethionine and ethionine in Escherichia coli,” Eur J Biochem. Jun. 1, 1995:230(2):788-96. cited by other Budisa, N et al., “Bioincorporation of telluromethionine into proteins: a promising new approach for X-ray structure analysis of proteins,” J Mol Biol. Jul. 25, 1997;270(4):616-23. cited by other Budisa, N et al., “Toward the experimental codon reassignment in vivo: protein building with an expanded amino acid repertoire,” FASEB J. Jan. 1999;13(1):41-51. cited by other Cai, X-Y et al., “Expression, Purification, and Characterization of an Activated Cytokine-Suppressive Anti-inflammatory Drug-Binding Protein 2 (CSBP2) Kinase from Baculovirus-Infected Insect Cells,” Protein Expression and Purification 1997; 10(2):263-74. cited by other Carbonell, LF et al., “Baculovirus-mediated expression of bacterial genes in dipteran and mammalian cells,” J Virol. Oct. 1985;56(1):153-60. cited by other Carrasco, M. and R. Brown, “A Versatile Set of Aminooxy Amino Acids for the Synthesis of Neoglycopeptides,” J. Org. Chem. (2003); 68(23): 8853-8858. cited by other Carter, P. “Site-directed mutagenesis,” Biochem J. Jul. 1, 1986; 237(1):1-7. cited by other Carter, P et al. “Improved oligonucleotide site-directed mutagenesis using M13 vectors” Nucleic Acids Res. Jun. 25, 1985;13(12):4431-43. cited by other Carter, P. “Improved oligonucleotide-directed mutagenesis using M13 vectors” Methods Enzymol. 1987;154:382-403. cited by other Chaiken, IM. “Semisynthetic peptides and proteins,” CRC Crit Rev Biochem. 1981;11(3):255-301. cited by other Chin, JW et al., “Addition of p-azido-L-phenylalanine to the genetic code of E. coli,” J Am Chem Soc. Aug. 7, 2002;124 (31):9026-7. cited by other Chin, JW et al., “Addition of a photocrosslinking amino acid to the genetic code of Escherichia coli,” Proc Natl Acad Sci U S A. Aug. 20, 2002:99(17):11020-4. Epub Aug. 1, 2002. cited by other Chin, JW et al., “An expanded eukaryotic genetic code,” Science. Aug. 15, 2003;301(5635):964-7. cited by other Chin, JW & P. G. Schultz, “In vivo photocrosslinking with unnatural amino acid mutagenesis,” Chembiochem. Nov. 4, 2002; 3(11): 1135-7. cited by other Christie, B.D. & Rapoport, H. “Synthesis of Optically Pure Pipecolates from L-Asparagine. Application to the Total Synthesis of (+)-Apovincamine through Amino Acid Decarbonylation and Iminium Ion Cyclization,” J. Org. Chem. 1985;50(8):1239-1246. cited by other Clark, R et al., “Long-acting growth hormones produced by conjugation with polyethylene glycol,” J Biol Chem. Sep. 6, 1996;271(36):21969-77. cited by other Corey, D.R., Schultz, P.G. “Generation of a hybrid sequence-specific single-stranded deoxyribonuclease,” Science 1987; 238(4832):1401-1403. cited by other Cornish, VW, et al., “Site-Specific Protein Modification Using a Ketone Handle,” J. Am. Chem. Soc. 1996; 118 (34):8150-8151. cited by other Cornish, VW et al., “Probing Protein Structure and Function with an Expanded Genetic Code,” Angew Chem Int Ed Engl,1995;34(6):621-33. cited by other Craig, J.C. et al. “Absolute Configuration of the Enantiomers of 7-Chloro-4 [[4-(diethylamino)-1-methylbutyl]amino] quinoline (Chloroquine),” J. Org. Chem. 1988; 53(6):1167-1170. cited by other Cregg, JM et al., “Pichia pastoris as a host system for transformations,” Mol Cell Biol. Dec. 1985;5(12):3376-85. cited by other Crick, FHC, et al. “General nature of the genetic code for proteins,” Nature. Dec. 30, 1961;192:1227-32. cited by other Dale et al., Oligonucleotide-directed random mutagenesis using the phosphorothioate method, Methods Mol. Biol.1996;57:369-374. cited by other Das, S et al., “Transformation of Kluyveromyces fragilis,” J Bacteriol. Jun. 1984;158(3):1165-7. cited by other Dawson, P. E. and S. B. H. Kent, “Synthesis of native proteins by chemical ligation,” Annu. Rev. Biochem. 2000; 69:923-60. cited by other De Boer, HA et al., “The tac promoter: a functional hybrid derived from the trp and lac promoters,” Proc Natl Acad Sci U S A. Jan. 1983;80(1):21-5. cited by other De Louvencourt, L et al., “Transformation of Kluyveromyces lactis by killer plasmid DNA,” J Bacteriol. May 1983;154(2):737-42. cited by other Holland, MJ et JP Holland., “Isolation and identification of yeast messenger ribonucleic acids coding for enolase, glyceraldehyde-3-phosphate dehydrogenase, and phosphoglycerate kinase,” Biochemistry. Nov. 14, 1978;17 (23):4900-7. cited by other Holland, MJ et al., “The primary structures of two yeast enolase genes. Homology between the 5' noncoding flanking regions of yeast enolase and glyceraldehyde-3-phosphate dehydrogenase genes,” J Biol Chem. Feb. 10, 1981;256(3):1385-95. cited by other Hsiao, CL et J Carbon, “High-frequency transformation of yeast by plasmids containing the cloned yeast ARG4 gene,” Proc Natl Acad Sci U S A. Aug. 1979;76(8):3829-33. cited by other Huisgen, R. in 1,3-Dipolar Cycloaddition Chemistry, vol. 1, 1984; Ed. Padwa A.; John Wiley and Sons, New York, p. 1-176. cited by other Hwang, KJ et al., “Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: a kinetic study,” Proc Natl Acad Sci U S A. Jul. 1980;77(7):4030-4. cited by other Ibba, M et al., “Substrate specificity is determined by amino acid binding pocket size in Escherichia coli phenylalanyl-tRNA synthetase,” Biochemistry. Jun. 14, 1994;33(23):7107-12. cited by other Ibba, M and H Hennecke, “Relaxing the substrate specificity of an aminoacyl-tRNA synthetase allows in vitro and in vivo synthesis of proteins containing unnatural amino acids,” FEBS Lett. May 15, 1995;364(3):272-5. cited by other Ito, H. et al., “Transformation of intact yeast cells treated with alkali cations,” J. Bacteriol. 1983; 153(1):163-8. cited by other Jackson, DY et al. “A designed peptide ligase for total synthesis of ribonuclease A with unnatural catalytic residues,” Science. Oct. 14, 1994;266(5183):243-7. cited by other Jakobsson, PJ et al., “Identification and characterization of a novel human microsomal glutathione S-transferase with leukotriene C4 synthase activity and significant sequence identity to 5-lipoxygenase-activating protein and leukotriene C4 synthase,” J Biol Chem. Sep. 6, 1996;271(36):22203-10. cited by other Jencks, W.P., “Studies on the Mechanism of Oxime and Semicarbazone Formation,” J. Am. Chem. Soc.; 1959; 81 (2):475-481. cited by other Joppich, M. et al. “Peptides Flanked by Two Polymer Chains, 1; Synthesis of Glycyl-L-tryptophylglycine Substituted by Poly(ethylene oxide) at both the Carboxy and the Amino End Groups,” Makromol. Chem. 1979;180:1381-4. cited by other Kaiser, ET. “Synthetic approaches to biologically active peptides and proteins including enzymes,” Acc Chem Res, (1989); 22(2):47-54. cited by other Kaiser, ET et al. “The chemical modification of enzymatic specificity,” Annu Rev Biochem. 1985;54:565-95. cited by other Kaiser, ET and DS Lawrence. “Chemical mutation of enzyme active sites,” Science. Nov. 2, 1984;226(4674):505-11. cited by other Karlin, S and SF Altschul “Applications and statistics for multiple high-scoring segments in molecular sequences,” Proc Natl Acad Sci U S A. Jun. 15, 1993;90(12):5873-7. cited by other Kayser, B., et al., “Alkyne bridged alpha-amino acids by palladium mediated coupling of alkynes with N-t-Boc-4-iodo-phenylalanine methyl ester,” Tetrahedron (1997); 53(7): 2475-2484. cited by other Kelly, JM and MJ Hynes, “Transformation of Aspergillus niger by the amdS gene of Aspergillus nidulans,” EMBO J. 1985; 4(2):475-479. cited by other Kiick, K. L. and D. A. Tirrell, “Protein Engineering by In Vivo Incorporation of Non-Natural Amino Acids: Control of Incorporation of Methionine Analogues by Methionyl-tRNA Synthetase,” Tetrahedron (2000), 56:9487-9493. cited by other Kiick, KL et al., “Incorporation of azides into recombinant proteins for chemoselective modification by the Staudinger ligation,” Proc Natl Acad Sci U S A. Jan. 8, 2002;99(1):19-24. Epub Dec. 18, 2001. cited by other Kim, DM and JR Swartz, “Regeneration of adenosine triphosphate from glycolytic intermediates for cell-free protein synthesis,” Biotechnol Bioeng. Aug. 20, 2001;74(4):309-16. cited by other Kim, DM and JR Swartz, “Oxalate improves protein synthesis by enhancing ATP supply in a cell-free system derived from Escherichia coli,” Biotechnology Letters, 2000; 22:1537-1542. cited by other Kim, DM, and JR Swartz, “Prolonging cell-free protein synthesis by selective reagent additions,” Biotechnol Prog. May-Jun. 2000;16(3):385-90. cited by other Kim, DM, and JR Swartz, “Prolonging cell-free protein synthesis with a novel ATP regeneration system,” Biotechnol. Bioeng. 1999;66(3):180-8. cited by other King, F.E. & Kidd, D.A.A. “A New Synthesis of Glutamine and of gamma-Dipeptides of Glutamic Acid from Phthylated Intermediates,” J. Chem. Soc. 1949; 3315-3319. cited by other Kingsman, AJ et al., “Replication in Saccharomyces cerevisiae of plasmid pBR313 carrying DNA from the yeast trpl region,” Gene. Oct. 1979;7(2):141-52. cited by other Kitts, PA et al. “Linearization of baculovirus DNA enhances the recovery of recombinant virus expression vectors,” Nucleic Acids Res. Oct. 11, 1990;18(19):5667-72. cited by other Klein, TM et al., “High-velocity microprojectiles for delivering nucleic acids into living cells,” Nature 1987; 327 (6117):70-73. cited by other Kobayashi, T. et al., “Structural basis for orthogonal tRNA specificities of tyrosyl-tRNA synthetases for genetic code expansion,” Nature Structural Biology (2003); 10(6):425-432. cited by other Kogan, TP. “The synthesis of substituted methoxy-poly(ethyleneglycol) derivatives suitable for selective protein modification,” Synthetic Comm. 1992; 22(16):2417-24. cited by other Kool, ET. “Synthetically modified DNAs as substrates for polymerases,” Curr Opin Chem Biol. Dec. 2000;4(6):602-8. cited by other Koskinen, A.M.P. & Rapoport, H. “Synthesis of 4-Substituted Prolines as Conformationally Constrained Amino Acid Analogues,” J. Org. Chem. (1989) 54(8):1859-1866. cited by other Kost, TA et al., “Production of a urokinase plasminogen activator-IgG fusion protein (uPA-IgG) in the baculovirus expression system,” Gene. Apr. 29, 1997;190(1):139-44. cited by other Kramer, W et al., “The gapped duplex DNA approach to oligonucleotide-directed mutation construction,” Nucleic Acids Res. Dec. 21, 1984;12(24):9441-56. cited by other Kramer, W & Fritz HJ. “Oligonucleotide-directed construction of mutations via gapped duplex DNA” Methods Enzymol. 1987;154:350-67. cited by other Kramer, W. et al., “Improved enzymatic in vitro reactions in the gapped duplex DNA approach to oligonucleotide-directed construction of mutations,” Nucleic Acids Res. Jul. 25, 1988;16(14B):7207. cited by other Kramer, B. et al., “Different base/base mismatches are corrected with different efficiencies by the methyl-directed DNA mismatch-repair system of E. coli,” Cell. Oct. 1984;38(3):879-87. cited by other Kreitman, RJ and I. Pastan “Purification and characterization of IL6-PE4E, a recombinant fusion of interleukin 6 with Pseudomonas exotoxin,” Bioconjug Chem. Nov.-Dec. 1993;4(6):581-5. cited by other Krieg, UC, et al. “Photocrosslinking of the signal sequence of nascent preprolactin to the 54-kilodalton polypeptide of the signal recognition particle,” Proc Natl Acad Sci U S A. Nov. 1986;83(22):8604-8. cited by other Kunitani, M. et al., “Reversed-phase chromatography of interleukin-2 muteins,” J Chromatogr. May 30, 1986;359:391-402. cited by other Kunkel, “The efficiency of oligonucleotide directed mutagenesis,” in Nucleic Acids & Molecular Biology 1987; Eckstein, F. and Lilley, D.M.J. eds.; Springer Verlag, Berlin; 124-135. cited by other Kunkel, TA “Rapid and efficient site-specific mutagenesis without phenotypic selection,” Proc Natl Acad Sci U S A. Jan. 1985;82(2):488-92. cited by other Kunkel, TA et al., “Rapid and efficient site-specific mutagenesis without phenotypic selection,” Methods Enzymol. 1987;154:367-82. cited by other Kunze, G et al., “Transformation of the industrially important yeasts Candida maltosa and Pichia guilliermondii,” J. Basic Microbiol. 1985; 25:141-4. cited by other Kurtz et al., “Integrative transformation of Candida albicans, using a cloned Candida ADE2 gene,” Mol Cell Biol. Jan. 1986;6(1):142-9. cited by other Kurtzhals, P et al., “Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo,” Biochem J. Dec. 15, 1995;312 ( Pt 3):725-31. cited by other Langer, R et al., “Biocompatibility of polymeric delivery systems for macromolecules,” J Biomed Mater Res. Mar. 1981;15(2):267-77. cited by other Langer, R. “Controlled release of macromolecules,” Chem. Tech. 1982; 12: 98-105. cited by other Liebman, JM et al., “When less is more: enhanced baculovirus production of recombinant proteins at very low multiplicities of infection,” Biotechniques. Jan. 1999;26(1):36-8, 40, 42. cited by other Ling, MM et Bh Robinson, “Approaches to DNA mutagenesis: an overview” Anal Biochem. Dec. 15, 1997;254 (2):157-78. cited by other Merigan, TC et al, “Human leukocyte interferon for the treatment of herpes zoster in patients with cancer,” N Engl J Med. May 4, 1978;298(18):981-7. cited by other Mitani, Y et al. “Cross talk of the interferon-alpha/beta signalling complex with gp130 for effective interleukin-6 signalling,” Genes Cells. Jul. 2001;6(7):631-40. cited by other Mitsui, Y. et al. “Structural, functional and evolutionary implications of the three-dimensional crystal structure of murine interferon-beta,” Pharmacol Ther. 1993;58(1):93-132. cited by other Mitsui, Y. et T. Senda. “Elucidation of the basic three-dimensional structure of type I interferons and its functional and evolutionary implications,” J Interferon Cytokine Res. Jun. 1997;17(6):319-26. cited by other Molineux, G. “Pegylation: engineering improved pharmaceuticals for enhanced therapy,” Cancer Treat Rev. Apr. 2002;28 Suppl A:13-6. cited by other Morikawa, O et al. “Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter,” Eur J Pharmacol. May 22, 1998;349(2-3):317-24. cited by other Mossner, R et al. “Modulation of serotonin transporter function by interleukin-4,” Life Sci. Jan. 12, 2001;68(8):873-80. cited by other Munschauer, FE III, et al. “Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis,” Clin Ther. Sep.-Oct. 1997;19(5):883-93. cited by other Nagata, S et al., “The structure of one of the eight or more distinct chromosomal genes for human interferon-alpha,” Nature. Oct. 2, 1980;287(5781):401-8. cited by other Nagata, S et al., “Synthesis in E. coli of a polypeptide with human leukocyte interferon activity,” Nature. Mar. 27, 1980;284(5754):316-20. cited by other Nakamura, K et al. “Genetic dissection of anxiety in autoimmune disease,” Hum Mol Genet. May 15, 2003;12 (10):1079-86. cited by other Neves, FO et al. “Overexpression of a synthetic gene encoding human alpha interferon in Escherichia coli,” Protein Expr Purif. Jun. 2004;35(2):353-9. cited by other Nguyen, VP et al. “Stat2 binding to the interferon-alpha receptor 2 subunit is not required for interferon-alpha signaling,” J Biol Chem. Mar. 22, 2002;277(12):9713-21. Epub Jan. 10, 2002. cited by other Okuse, C. et al. “Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy,” Antiviral Res. Jan. 2005;65(1):23-34. cited by other Oritani, K et al. “Limitin: An interferon-like cytokine that preferentially influences B-lymphocyte precursors,” Nat Med. Jun. 2000;6(6):659-66. cited by other Oritani, K et al. “Type I interferons and limitin: a comparison of structures, receptors, and functions,” Cytokine Growth Factor Rev. Dec. 2001;12(4):337-48. cited by other Palleroni, AV et al. “Interferon immunogenicity: preclinical evaluation of interferon-alpha 2a,” J Interferon Cytokine Res. Jul. 1997;17 Suppl 1:S23-7. cited by other Pappas, SC. “The Pharmacokinetics of Pegylated Interferon in Renal Disease,” in HCV Advocate Conference Reports, 2002 Reports, Session IV. cited by other Pattyn, E. et al. “Dimerization of the interferon type I receptor IFNaR2-2 is sufficient for induction of interferon effector genes but not for full antiviral activity,” J Biol Chem. Dec. 3, 1999;274(49):34838-45. cited by other Pawlotsky, JM et al. “Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations,” J Virol. Apr. 1998;72(4):2795-805. cited by other Pedder, SC. “Pegylation of interferon alfa: structural and pharmacokinetic properties,” Semin Liver Dis. 2003;23 Suppl 1:19-22. cited by other Peleg-Shulman, T et al. “Reversible PEGylation: a novel technology to release native interferon alpha2 over a prolonged time period,” J Med Chem. Sep. 23, 2004;47(20):4897-904. cited by other Pestka, S. “The human interferons—from protein purification and sequence to cloning and expression in bacteria: before, between, and beyond,” Arch Biochem Biophys. Feb. 15, 1983;221(1):1-37. cited by other Pestka, S. et al. “Interleukin-10 and related cytokines and receptors,” Annu Rev Immunol. 2004;22:929-79. cited by other Pfeffer, LM. “Biologic activities of natural and synthetic type I interferons,” Semin Oncol. Jun. 1997;24(3 Suppl 9): S9-63-S9-69. cited by other Piehler, J and G. Schreiber. “Mutational and structural analysis of the binding interface between type I interferons and their receptor lfnar2,” J Mol Biol. Nov. 19, 1999;294(1):223-37. cited by other Piehler, J. et al. “New structural and functional aspects of the type I interferon-receptor interaction revealed by comprehensive mutational analysis of the binding interface,” J Biol Chem. Dec. 22, 2000;275(51):40425-33. cited by other Platanias, LC et EN Fish. “Signaling pathways activated by interferons,” Exp Hematol. Nov. 1999;27(11):1583-92. cited by other Platanias, LC et al. “CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors,” Exp Hematol. Aug. 1999;27(8):1315-21. cited by other Platis, D et GR Foster. “Activity of hybrid type I interferons in cells lacking Tyk2: a common region of IFN-alpha 8 induces a response, but IFN-alpha2/8 hybrids can behave like IFN-beta,” J Interferon Cytokine Res. Nov. 2003;23 (11):655-66. cited by other Radhakrishnan, R et al. “Zinc mediated dimer of human interferon-alpha 2b revealed by X-ray crystallography,” Structure. Dec. 15, 1996;4(12):1453-63. cited by other Roisman, LC et al. “Structure of the interferon-receptor complex determined by distance constraints from double-mutant cycles and flexible docking,” Proc Natl Acad Sci U S A. Nov. 6, 2001;98(23):13231-6. cited by other Rosendahl, MS et al. “A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation,” Bioconjug Chem. Jan.-Feb. 2005;16(1):200-7. cited by other Rubinstein, S et al. “Convenient assay for interferons,” J Virol. Feb. 1981;37(2):755-8. cited by other Runkel, L et al. “Systematic mutational mapping of sites on human interferon-beta-1a that are important for receptor binding and functional activity,” Biochemistry. Mar. 14, 2000;39(10):2538-51. cited by other Runkel, L et al, “Differences in activity between alpha and beta type I interferons explored by mutational analysis,” J Biol Chem. Apr. 3, 1998;273(14):8003-8. cited by other Runkel, L et al. “Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta),” Pharm Res. Apr. 1998;15(4):641-9. cited by other Schaefer, M. et al. “Interferon alpha (IFNalpha) and psychiatric syndromes: a review,” Prog Neuropsychopharmacol Biol Psychiatry. May 2002;26(4):731-46. cited by other Schaefer, M. et al. “Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha,” Brain Behav Immun. Nov. 2004;18(6):555-62. cited by other Schultz, U et al. “The interferon system of non-mammalian vertebrates,” Dev Comp Immunol. May 3, 2004;28 (5):499-508. cited by other Kostyo, JL et al., “Biological characterization of purified native 20-kDa human growth hormone” Biochim Biophys Acta. Sep. 11, 1987;925(3):314-24. cited by other Lee, N. et al., “Interferon-alpha 2 variants in the human genome,” J Interferon Cytokine Res. Apr. 1995;15(4):341-9. cited by other Leung, DW, et al., “Growth hormone receptor and serum binding protein: purification, cloning and expression,” Nature. Dec. 10-16, 1987;330(6148):537-43. cited by other Lewis, UJ, et al., “A naturally occurring structural variant of human growth hormone” J Biol Chem. Apr. 25, 1978;253 (8):2679-87. cited by other Lewis, UJ, et al., “An interchain disulfide dimer of human growth hormone” J Biol Chem. Jun. 10, 1977;252 (11):3697-702. cited by other Li, CH, “Human growth hormone: 1974-1981,” Mol Cell Biochem. Jul. 7, 1982;46(1):31-41. cited by other MacGillivray, MH et al., “Outcome of a four-year randomized study of daily versus three times weekly somatropin treatment in prepubertal naive growth hormone-deficient children. Genentech Study Group.” J Clin Endocrinol Metab. May 1996; 81(5):1806-9. cited by other Matthews, DJ et al., “A sequential dimerization mechanism for erythropoietin receptor activation,” Proc Natl Acad Sci U S A. Sep. 3, 1996;93(18):9471-6. cited by other McFarland, KC et al., “Lutropin-choriogonadotropin receptor: an unusual member of the G protein-coupled receptor family,” Science. Aug. 4, 1989;245(4917):494-9. cited by other Abe, S et al. “Effects of chronic administration of interferon alpha A/D on serotonergic receptors in rat brain,” Neurochem Res. Mar. 1999;24(3):359-63. cited by other Acosta-Rivero, N. et al. “Improvement of human interferon HUIFNalpha2 and HCV core protein expression levels in Escherichia coli but not of HUIFNalpha8 by using the tRNA(AGA/AGG),” Biochem Biophys Res Commun. Sep. 6, 2002;296(5):1303-9. cited by other Adolf, GR et al., “Natural human interferon-alpha 2 is O-glycosylated,” Biochem J. Jun. 1, 1991;276 ( Pt 2):511-8. cited by other Ahmad, S. et al. “The type I interferon receptor mediates tyrosine phosphorylation of the CrkL adaptor protein,” J Biol Chem. Nov. 28, 1997;272(48):29991-4. cited by other Ahn, J et S. Flamm. “Peginterferon-alpha(2b) and ribavirin,” Expert Rev Anti Infect Ther. Feb. 2004;2(1):17-25. cited by other Aoki, K et al. “Limitin, an interferon-like cytokine, transduces inhibitory signals on B-cell growth through activation of Tyk2, but not Stat1, followed by induction and nuclear translocation of Daxx,” Exp Hematol. Dec. 2003;31(12):1317-22. cited by other Arora, D et N Khanna. “Method for increasing the yield of properly folded recombinant human gamma interferon from inclusion bodies,” J Biotechnol. Dec. 10, 1996;52(2):127-33. cited by other Bailon, P et al., “Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C,” Bioconjug Chem. Mar.-Apr. 2001;12(2):195-202. cited by other Bannink, M. et al. “Platelet MAO activity during treatment with pegylated interferon-alfa in melanoma patients,” Prog Neuropsychopharmacol Biol Psychiatry. Jan. 2005;29(1):109-14. Epub Nov. 18, 2004. cited by other Baron, E et S. Narula, “From cloning to a commercial realization: human alpha interferon,” Crit Rev Biotechnol. 1990:10(3):179-90. cited by other Bartenschlager, R et al. “Replication of the hepatitis C virus in cell culture,” Antiviral Res. Oct. 2003;60(2):91-102. cited by other Basu, L et al. “The antiviral action of interferon is potentiated by removal of the conserved IRTAM domain of the IFNAR1 chain of the interferon alpha/beta receptor: effects on JAK-STAT activation and receptor down-regulation,” Virology. Mar. 1, 1998;242(1):14-21. cited by other Beldarrain, A. et al. “Purification and conformational properties of a human interferon alpha2b produced in Escherichia coli,” Biotechnol Appl Biochem. Jun. 2001;33(Pt 3):173-82. cited by other Benoit, P. et al. “A monoclonal antibody to recombinant human IFN-alpha receptor inhibits biologic activity of several species of human IFN-alpha, IFN-beta, and IFN-omega. Detection of heterogeneity of the cellular type I IFN receptor,” J Immunol. Feb. 1, 1993;150(3):707-16. cited by other Biron, CA. “Interferons alpha and beta as immune regulators—a new look,” Immunity. Jun. 2001;14(6):661-4. cited by other Blatt, LM et al. “The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon,” J Interferon Cytokine Res. Jul. 1996;16(7):489-99. cited by other Blight, KJ et al. “Efficient initiation of HCV RNA replication in cell culture,” Science. Dec. 8, 2000;290(5498):1972-4. cited by other Blight, KJ et al. “Highly Permissive Cell Lines for Subgenomic and Genomic Hepatitis C Virus RNA Replication,” J Virol. Dec. 2002;76(24):13001-14. cited by other Blight, KJ et al. “Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture,” J Virol. Mar. 2003;77 (5):3181-90. cited by other Bocci, V. “How a physiologist viewed and lived with the interferon problem,” J Biol Regul Homeost Agents. Oct.-Dec. 2003;17(4):289-94. cited by other Bonnem, EM et al. “Interferon-alpha: current status and future promise,” J Biol Response Mod. Dec. 1984;3(6):580-98. cited by other Boulestin, A et al. “Convenient biological assay for polyethylene glycol-interferons in patients with hepatitis C,” Antimicrob Agents Chemother. Sep. 2004:48(9):3610-2. cited by other Brierley, MM et EN Fish. “Review: IFN-alpha/beta receptor interactions to biologic outcomes: understanding the circuitry,” J Interferon Cytokine Res. Aug. 2002;22(8):835-45. cited by other Caliceti, P. “Pharmacokinetics of pegylated interferons: what is misleading?,” Dig Liver Dis. Nov. 2004;36 Suppl 3: S334-9. cited by other Capon, DJ et al. “Two distinct families of human and bovine interferon-alpha genes are coordinately expressed and encode functional polypeptides,” Mol Cell Biol. Apr. 1985;5(4):768-79. cited by other Certa, U. et al. “Expression modes of interferon-alpha inducible genes in sensitive and resistant human melanoma cells stimulated with regular and pegylated interferon-alpha,” Gene. Oct. 2, 2003;315:79-86. cited by other Certa, U et al. “High density oligonucleotide array analysis of interferon-alpha2a sensitivity and transcriptional response in melanoma cells,” Br J Cancer. Jul. 6, 2001;85(1):107-14. cited by other Chang, C-C J. et al. “Evolution of a cytokine using DNA family shuffling,” Nat Biotechnol. Aug. 1999;17(8):793-7. cited by other Chatelut, E. et al. “A pharmacokinetic model for alpha interferon administered subcutaneously,” Br J Clin Pharmacol. Apr. 1999;47(4):365-71. cited by other Cheney, IW et al. “Comparative analysis of anti-hepatitis C virus activity and gene expression mediated by alpha, beta, and gamma interferons,” J Virol. Nov. 2002;76(21):11148-54. cited by other Chill, JH et al. “The human type I interferon receptor: NMR structure reveals the molecular basis of ligand binding,” Structure (Camb). Jul. 2003;11(7):791-802. cited by other Chill, JH et al. “The human interferon receptor: NMR-based modeling, mapping of the IFN-alpha 2 binding site, and observed ligand-induced tightening,” Biochemistry. Mar. 19, 2002:41(11):3575-85. cited by other Chuntharapai, A. et al. “Determination of residues involved in ligand binding and signal transmission in the human IFN-alpha receptor 2,” J Immunol. Jul. 15, 1999;163(2):766-73. cited by other Cleary, CM et al. “Knockout and reconstitution of a functional human type I interferon receptor complex,” J Biol Chem. Jul. 22, 1994;269(29):18747-9. cited by other Colamonici, OR et al. “Complementation of the interferon alpha response in resistant cells by expression of the cloned subunit of the interferon alpha receptor. A central role of this subunit in interferon alpha signaling,” J Biol Chem. Apr. 1, 1994;269(13):9598-602. cited by other Constantinescu, SN et al. “Expression and signaling specificity of the IFNAR chain of the type I interferon receptor complex,” Proc Natl Acad Sci U S A. Nov. 7, 1995;92(23):10487-91. cited by other Craven, RA et al. “Identification of proteins regulated by interferon-alpha in resistant and sensitive malignant melanoma cell lines,” Proteomics. Dec. 2004;4(12):3998-4009. cited by other Cutrone, EC and JA Langer. “Identification of critical residues in bovine IFNAR-1 responsible for interferon binding,” J Biol Chem. May 18, 2001;276(20):17140-8. Epub Feb. 7, 2001. cited by other Czerwionka-Szaflarska, M. et al. “Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children,” Med Sci Monit 2000; 6(5):964-970. cited by other Davis, GL et al. “Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group,” N Engl J Med. Nov. 30, 1989;321(22):1501-6. cited by other Alam, KS et al. “Expression and purification of a mutant human growth hormone that is resistant to proteolytic cleavage by thrombin, plasmin and human plasma in vitro,” J Biotechnol. Oct. 27, 1998;65(2-3):183-90. cited by other Baumann, G., “Growth hormone heterogeneity: genes, isohormones, variants, and binding proteins,” Endocr Rev. Nov. 1991;12(4):424-49. cited by other Bazan, JF. “Haemopoietic receptors and helical cytokines,” Immunology Today (1990); 11: 350-354. cited by other Bazan, JF, “Structural design and molecular evolution of a cytokine receptor superfamily,” Proc Natl Acad Sci U S A. Sep. 1990;87(18):6934-8. cited by other Bazan, JF et DB McKay. “Unraveling the structure of IL-2,” Science. Jul. 17, 1992;257(5068):410-3. cited by other Becker, GW et al. “Isolation and characterization of a sulfoxide and a desamido derivative of biosynthetic human growth hormone,” Biotechnol Appl Biochem. Aug. 1988;10(4):326-37. cited by other Boutin, JM, et al., “Cloning and expression of the rat prolactin receptor, a member of the growth hormone/prolactin receptor gene family,” Cell. Apr. 8, 1988;53(1):69-77. cited by other Brostedt, P. and Roos, P., “Isolation of dimeric forms of human pituitary growth hormone,” Prep Biochem. 1989;19 (3):217-29. cited by other Senda, T. et al., “Refined Crystal Structure of Recombinant Murine Interferon-β at 2.15 Å Resolution,” J Mol Biol. Oct. 13, 1995;253(1):187-207. cited by other Senda, T et al. “Three-dimensional crystal structure of recombinant murine interferon-beta,” EMBO J. Sep. 1992;11 (9):3193-201. cited by other Seto, MH et al. “Homology model of human interferon-alpha 8 and its receptor complex,” Protein Sci. Apr. 1995;4 (4):655-70. cited by other Sharma, VK et DS Kalonia. “Polyethylene glycol-induced precipitation of interferon alpha-2a followed by vacuum drying: development of a novel process for obtaining a dry, stable powder,” AAPS PharmSci. Jan. 26, 2004;6(1):E4. cited by other Shepard, J. et al. “Pegylated interferon alpha-2a and -2b in combination with riboflavin in the treatment of chronic Hepatitis C: a systematic review and economic evaluation,” Health Technology Assessment Oct. 2004; 8(39). cited by other Sprang, SR et al. “Cytokine structural taxonomy and mechanisms of receptor engagement,” Curr. Opin. Struct. Biol. 1993; 3:815-827. cited by other Stewart, TA. “Neutralizing interferon alpha as a therapeutic approach to autoimmune diseases,” Cytokine Growth Factor Rev. Apr. 2003;14(2):139-54. cited by other Stewart, AG et al, “Chemical mutagenesis of human interferon-beta: construction, expression in E. coli, and biological activity of sodium bisulfite-induced mutations,” DNA. Apr. 1987:6(2):119-28. cited by other Streuli, M. et al., “At least three human type alpha interferons: structure of alpha 2,” Science. Sep. 19, 1980;209 (4463):1343-7. cited by other Subramaniam, PS et al. “Differential recognition of the type I interferon receptor by interferons tau and alpha is responsible for their disparate cytotoxicities,” Proc Natl Acad Sci U S A. Dec. 19, 1995;92(26):12270-4. cited by other Tan, SL et al. “Strategies for hepatitis C therapeutic intervention: now and next,” Curr Opin Pharmacol. Oct. 2004;4 (5):465-70. cited by other Taniguchi, T. “The nucleotide sequence of human fibroblast interferon cDNA,” Gene. Jun. 1980;10(1):11-5. cited by other Taniguchi, T. et al., “Human leukocyte and fibroblast interferons are structurally related,” Nature. Jun. 19, 1980;285 (5766):547-9. cited by other Tejedor, F. et al., “Iodination of biological samples without loss of functional activity,” Anal Biochem. Nov. 15, 1982;127(1):143-9. cited by other Tilg, H. “New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine,” Gastroenterology. Mar. 1997;112(3):1017-21. cited by other Ullrich, A et al., “Nucleotide sequence of a portion of human chromosome 9 containing a leukocyte interferon gene cluster,” J Mol Biol. Apr. 15, 1982;156(3):467-86. cited by other Valenzuela, D et al. “Is sequence conservation in interferons due to selection for functional proteins?,” Nature. Feb. 21-27, 1985;313(6004):698-700. cited by other Van Pesch, V et al. “Characterization of the murine alpha interferon gene family,” J Virol. Aug. 2004;78(15):8219-28. cited by other Walker, MP et al. “Hepatitis C virus therapies: current treatments, targets and future perspectives,” Antivir Chem Chemother. Jan. 2003;14(1):1-21. cited by other Wang, Q et al. “Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1,” Blood. Sep. 15, 2000;96(6):2093-9. cited by other Wang, YS et al. “Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications,” Adv Drug Deliv Rev. Jun. 17, 2002;54(4):547-70. cited by other Wang, Y-X et al. “Fever of recombinant human interferon-alpha is mediated by opioid domain interaction with opioid receptor inducing prostaglandin E2,” J Neuroimmunol. Nov. 2004;156(1-2):107-12. cited by other Wang, Y-X et al. “Distinct domains of IFNalpha mediate immune and analgesic effects respectively,” J Neuroimmunol. Aug. 1, 2000;108(1-2):64-7. cited by other Wang, Y-X et al. “Analgesic domains of interferon-alpha,” Neuroreport. Mar. 26, 2001;12(4):857-9. cited by other Wang, YX et al. “The analgesic domain of interferon-alpha2b contains an essential proline(39) residue,” Neuroimmunomodulation. 2002;10(1):5-8. cited by other Weissmann, C. et al., “Structure and expression of human IFN-alpha genes,” Philos Trans R Soc Lond B Biol Sci. Sep. 24, 1982;299(1094):7-28. cited by other Whaley, AE et al., “Identification and cellular localization of unique interferon mRNA from human placenta,” J Biol Chem. Apr. 8, 1994;269(14):10864-8. cited by other Wichers, MC et M Maes. “The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression,” J Psychiatry Neurosci. Jan. 2004;29(1):11-7. cited by other Williams, CD and DC Linch, “Interferon alfa-2a,” Br J Hosp Med. May 7-20, 1997;57(9):436-9. cited by other Yong, VW et al. “Interferon beta in the treatment of multiple sclerosis: mechanisms of action,” Neurology. Sep. 1998; 51(3):682-9. cited by other Youngster, S. et al., “Structure, Biology, and Therapeutic Implications of Pegylated Interferon Alpha-2b,” Current Pharma Design 2002; 8(24):2139-2157. cited by other Zella, D et al. “Recombinant IFN-alpha (2b) increases the expression of apoptosis receptor CD95 and chemokine receptors CCR1 and CCR3 in monocytoid cells,” J Immunol. Sep. 15, 1999;163(6):3169-75. cited by other Zoll, J et al. “The mengovirus leader protein suppresses alpha/beta interferon production by inhibition of the iron/ferritin-mediated activation of NF-kappa B,” J Virol. Oct. 2002;76(19):9664-72. cited by other Zoon, KC et al. “Production of human lymphoblastoid interferon by Namalva cells,” J Clin Microbiol. Jan. 1978;7 (1):44-51. cited by other Zoon, KC et al. “Purification and characterization of multiple components of human lymphoblastoid interferon-alpha,” J Biol Chem. Jul. 25, 1992;267(21):15210-6. cited by other Zoon, KC et al., (1986) In, The Biology of the Interferon System. Cantell and Schellenkens, Eds., Martinus Nyhoff Publishers, Amsterdam. cited by other Milburn, MV et al., “A novel dimer configuration revealed by the crystal structure at 2.4 A resolution of human interleukin-5” Nature 1993; 363:172-176. cited by other Mills, JB., et al., “Fragments of human growth hormone produced by digestion with thrombin: chemistry and biological properties,” Endocrinology. Aug. 1980;107(2):391-9. cited by other Mordenti, J., et al., “Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins,” Pharm Res. Nov. 1991;8(11):1351-9. cited by other Mott, HR and ID Campbell. “Four-helix bundle growth factors and their receptors: protein-protein interactions” Curr Opin Struct Biol. Feb. 1995;5(1):114-21. cited by other Murgolo, NJ et al., “A homology model of human interferon alpha-2” Proteins. Sep. 1993;17(1):62-74. cited by other Paonessa, G. et al., Two distinct and independent sites on IL-6 trigger gp 130 dimer formation and signalling EMBO J. May 1, 1995;14(9):1942-51. cited by other Powers, R. et al., “Three-dimensional solution structure of human interleukin-4 by multidimensional heteronuclear magnetic resonance spectroscopy,” Science. Jun. 19, 1992;256(5064):1673-7. cited by other Redfield, C. et al., “Secondary structure and topology of human interleukin 4 in solution” Biochemistry. Nov. 19, 1991;30(46):11029-35. cited by other Seeburg, PH. “The human growth hormone gene family: nucleotide sequences show recent divergence and predict a new polypeptide hormone,” DNA. 1982;1(3):239-49. cited by other Silva, CM et al., “Characterization and cloning of STAT5 from IM-9 cells and its activation by growth hormone,” Mol Endocrinol. May 1996;10(5):508-18. cited by other Souza, SC et al., “A single arginine residue determines species specificity of the human growth hormone receptor,” Proc Natl Acad Sci U S A. Feb. 14, 1995;92(4):959-63. cited by other Spencer, SA., et al., “Rabbit liver growth hormone receptor and serum binding protein. Purification, characterization, and sequence,” J Biol Chem. Jun. 5, 1988;263(16):7862-7. cited by other Van Der Lely, AJ et al., “Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist” Lancet. Nov. 24, 2001;358(9295):1754-9. cited by other Hu, R. et al., “Evidence for multiple binding sites for several components of human lymphoblastoid interferon-alpha,” J Biol Chem. Jun. 15, 1993;268(17):12591-5. cited by other Hwang, SY et al. “A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses,” Proc Natl Acad Sci U S A. Nov. 21, 1995;92(24):11284-8. cited by other Iolascon, A et al. “Genes transcriptionally modulated by interferon alpha2a correlate with the cytokine activity,” Haematologica. Sep. 2004;89(9):1046-53. cited by other Ishida, N. et al. “Differential effects of a novel IFN-zeta/limitin and IFN-alpha on signals for Daxx induction and Crk phosphorylation that couple with growth control of megakaryocytes,” Exp Hematol. Apr. 2005;33(4):495-503. cited by other Jiang, CL et al. “Analgesic effect of interferon-alpha via mu opioid receptor in the rat,” Neurochem Int. Mar. 2000;36 (3):193-6. cited by other Jones, TD et al. “The development of a modified human IFN-alpha2b linked to the Fc portion of human IgG1 as a novel potential therapeutic for the treatment of hepatitis C virus infection,” J Interferon Cytokine Res. Sep. 2004;24 (9):560-72. cited by other Joshua, DE et al., “Role of alpha interferon in multiple myeloma,” Blood Rev. Dec. 1997:11(4):191-200. cited by other Jungwirth, C et al. “Chicken interferon consensus sequence-binding protein (ICSBP) and interferon regulatoryfactor (IRF) 1 genes reveal evolutionary conservation in the IRF gene family,” Proc Natl Acad Sci U S A. Apr. 11, 1995;92(8):3105-9. cited by other Kanda, T. et al. “Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: ribavirin induces mutagenesis in HCV RNA,” J Viral Hepat. Nov. 2004;11(6):479-87. cited by other Karpusas, M. et al., “The crystal structure of human interferon beta at 2.2-A resolution,” Proc Natl Acad Sci U S A. Oct. 28, 1997;94(22):11813-8. cited by other Karpusas, M. et al. “The structure of human interferon-beta: implications for activity,” Cell Mol Life Sci. Nov. 1998;54 (11):1203-16. cited by other Kashima, H. et al. “Interferon alfa-n1 (Wellferon) in juvenile onset recurrent respiratory papillomatosis: results of a randomized study in twelve collaborative institutions,” Laryngoscope. Mar. 1988;98(3):334-40. cited by other Kawamoto, S-I, et al. “A new interferon, limitin, displays equivalent immunomodulatory and antitumor activities without myelosuppressive properties as compared with interferon-alpha,” Exp Hematol. Sep. 2004;32(9):797-805. cited by other Kawamoto, S-I, et al. “Antiviral activity of limitin against encephalomyocarditis virus, herpes simplex virus, and mouse hepatitis virus: diverse requirements by limitin and alpha interferon for interferon regulatory factor 1,” J Virol. Sep. 2003;77(17):9622-31. cited by other Kitagami, T. et al. “Mechanism of systemically injected interferon-alpha impeding monoamine biosynthesis in rats: role of nitric oxide as a signal crossing the blood-brain barrier,” Brain Res. Jul. 18, 2003;978(1-2):104-14. cited by other Klaus, W. et al. “The three-dimensional high resolution structure of human interferon alpha-2a determined by heteronuclear NMR spectroscopy in solution,” J Mol Biol. Dec. 12, 1997;274(4):661-75. cited by other Knobler, R. L. et al., “Systemic alpha-interferon therapy of multiple sclerosis,” Neurology. Oct. 1984;34(10):1273-9. cited by other Kontsek, P. et al., “Immunogenicity of interferon-alpha 2 in therapy: structural and physiological aspects,” Acta Virol. Feb. 1999;43(1):63-70. cited by other Koyanagi, S. et al. “Chronopharmacological study of interferon-alpha in mice,” J Pharmacol Exp Ther. Oct. 1997;283 (1):259-64. cited by other Lamken, P et al. “Ligand-induced assembling of the type I interferon receptor on supported lipid bilayers,” J Mol Biol. Jul. 30, 2004:341(1):303-18. cited by other Larkin, J et al. “Synergistic antiviral activity of human interferon combinations in the hepatitis C virus replicon system,” J Interferon Cytokine Res. May 2003;23(5):247-57. cited by other Lawn, RM et al. “DNA sequence of a major human leukocyte interferon gene,” Proc Nati Acad Sci U S A. Sep. 1981;78(9):5435-9. cited by other Lawn, RM et al., “DNA sequence of two closely linked human leukocyte interferon genes,” Science. Jun. 5, 1981;212 (4499):1159-62. cited by other Levy, WP et al. “Amino acid sequence of a human leukocyte interferon,” Proc Natl Acad Sci U S A. Oct. 1981;78 (10):6186-90. cited by other Lewerenz, M et al. “Shared receptor components but distinct complexes for alpha and beta interferons,” J Mol Biol. Sep. 25, 1998;282(3):585-99. cited by other Li, J et RM Roberts. “Interferon-tau and interferon-alpha interact with the same receptors in bovine endometrium. Use of a readily iodinatable form of recombinant interferon-tau for binding studies,” J Biol Chem. May 6, 1994;269 (18):13544-50. cited by other Li, Y et al. “Morphine enhances hepatitis C virus (HCV) replicon expression,” Am J Pathol. Sep. 2003;163(3):1167-75. cited by other Lohmann, V et al. “Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line,” Science. Jul. 2, 1999;285(5424):110-3. cited by other Lund, B et al., “Novel cluster of alpha-interferon gene sequences in a placental cosmid DNA library,” Proc Nati Acad Sci U S A. Apr. 1984;81(8):2435-9. cited by other Lutfalla, G. et al. “The structure of the human interferon alpha/beta receptor gene,” J Biol Chem. Feb. 5, 1992;267 (4):2802-9. cited by other Luxon, BA “Pegylated interferons for the treatment of chronic hepatitis C infection,” Clin Ther. Sep. 2002;24 (9):1363-83. cited by other Makino, M et al. “Involvement of central opioid systems in human interferon-alpha induced immobility in the mouse forced swimming test,” Br J Pharmacol. Jul. 2000;130(6):1269-74. cited by other Makoff, AJ et AE Smallwood. “The use of two-cistron constructions in improving the expression of a heterologous gene in E. coli,” Nucleic Acids Res. Apr. 11, 1990;18(7):1711-8. cited by other Manns, MP et al. “Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial,” Lancet. Sep. 22, 2001;358(9286):958-65. cited by other Masci, P. et al. “New and modified interferon alfas: preclinical and clinical data,” Curr Oncol Rep. Mar. 2003;5 (2):108-13. cited by other Matthes, HWD, et al. “Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene,” Nature. Oct. 31, 1996;383(6603):819-23. cited by other McNeill, TA, “Interferon assay,” J Immunol Methods. 1981;46(2):121-7. cited by other Meister, A et al., “Biological activities and receptor binding of two human recombinant interferons and their hybrids,” J Gen Virol. Aug. 1986;67 ( Pt 8):1633-43. cited by other Mercer, DF et al. “Hepatitis C virus replication in mice with chimeric human livers,” Nat Med. Aug. 2001;7(8):927-33. cited by other De Vos, AM, et al., “Human growth hormone and extracellular domain of its receptor: crystal structure of the complex” Science. Jan. 17, 1992;255(5042):306-12. cited by other Diederichs, K., et al. “Novel fold and putative receptor binding site of granulocyte-macrophage colony-stimulating factor” Science (1991) 154: 1779-1782. cited by other Fuh, G., et al., “Rational design of potent antagonists to the human growth hormone receptor,” Science. Jun. 19, 1992;256(5064):1677-80. cited by other Goeddel, DV, et al., “Direct expression in Escherichia coli of a DNA sequence coding for human growth hormone” Nature. Oct. 18, 1979;281(5732):544-8. cited by other Gout, P. W., et al. “Prolactin-stimulated growth of cell cultures established from malignant Nb rat lymphomas,” Cancer Res. Jul. 1980;40(7):2433-6. cited by other Hill, CP et al., “The Structure of Granulocyte-Colony-Stimulating Factor and its Relationship to Other Growth Factors,” Proc. Natl. Acad. Sci.USA (1993)) 90:5167-71. cited by other Hughes, JP and HG Friesen, “The nature and regulation of the receptors for pituitary growth hormone” Annu Rev Physiol. 1985;47:469-82. cited by other Igout, A., et al., “Expression and secretion of the human placental growth hormone in Escherichia coli” Nucleic Acids Res. May 25, 1989;17(10):3998. cited by other Isaksson, OG, et al., “Mode of action of pituitary growth hormone on target cells” Annu Rev Physiol. 1985;47:483-99. cited by other Liu, H. et al. “A Method for the Generation of Glycoprotein Mimetics,” J. Am. Chem. Soc. 2003 125(7): 1702-1703. cited by other Liu, D.R. & Schultz, P.G. “Progress toward the evolution of an organism with an expanded genetic code,” Proc Natl Acad Sci U S A. Apr. 27, 1999;96(9):4780-5. cited by other Lorimer, I. A. et I. Pastan, “Random recombination of antibody single chain Fv sequences after fragmentation with DNasel in the presence of Mn2+,” Nucleic Acids Res. Aug. 11, 1995;23(15):3067-8. cited by other Lu, T. et al. “Probing ion permeation and gating in a K +channel with backbone mutations in the selectivity filter,” Nature Neurosci. Mar. 2001;4(3):239-246. cited by other Luckow, VA and MD Summers, “High level expression of nonfused foreign genes with Autographa californica nuclear polyhedrosis virus expression vectors,” Virology. May 1989;170(1):31-9. cited by other Ma, C et al., “In vitro protein engineering using synthetic tRNA(Ala) with different anticodons,” Biochemistry. Aug. 10, 1993;32(31):7939-45. cited by other Magliery, TJ et al. “Expanding the Genetic Code: Selection of Efficient Suppressors of Four-base Codons and Identification of “Shifty” Four-base Codons with a Library Approach in Escherichia coli,” J Mol Biol. Mar. 30, 2001;307 (3):755-69. cited by other Mahal, L. K., et al., “Engineering chemical reactivity on cell surfaces through oligosaccharide biosynthesis,” Science. May 16, 1997;276(5315):1125-8. cited by other Makrides, SC et al., “Extended in vivo half-life of human soluble complement receptor type 1 fused to a serum albumin-binding receptor,” J Pharmacol Exp Ther. Apr. 1996;277(1):534-42. cited by other Mamot, C, et al., “Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells,” Cancer Res. Jun. 15, 2003;63(12):3154-61. cited by other Mandecki, W. Oligonucleotide-directed double-strand break repair in plasmids of Escherichia coli: a method for site-specific mutagenesis, Proc Natl Acad Sci U S A. Oct. 1986;83(19):7177-81. cited by other Mann, SG and LA King, “Efficient transfection of insect cells with baculovirus DNA using electroporation,” J Gen Virol. Dec. 1989;70 (Pt 12):3501-5. cited by other Matsoukas, JM et al., “Differences in backbone structure between angiotensin II agonists and type I antagonists,” J Med Chem. Nov. 10, 1995;38(23):4660-9. cited by other McMinn, DL et al., “Efforts toward Expansion of the Genetic Alphabet: DNA Polymerase Recognition of a Highly Stable, Self-Pairing Hydrophobic Base,” J. Am. Chem. Soc. 1999; 121(49):11585-6. cited by other Meggers, E et al., “A Novel Copper-Mediated DNA Base Pair,” J. Am. Chem. Soc. 2000; 122(43):10714-10715. cited by other Mehvar, R.,“Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation” J Pharm Pharm Sci. Jan.-Apr. 2000;3(1):125-36. cited by other Mendel, D, et al. “Site-directed mutagenesis with an expanded genetic code,” Annu Rev Biophys Biomol Struct. 1995;24:435-62. cited by other Miller, LK, “Baculoviruses as gene expression vectors,” Ann. Rev. Microbiol. 1988; 42:177-99. cited by other Miller, LK. “Insect baculoviruses: powerful gene expression vectors,” Bioessays. Oct. 1989;11(4):91-5. cited by other Miller, JC et al. “Flash decaging of tyrosine sidechains in an ion channel,” Neuron. Apr. 1998;20(4):619-24. cited by other Minks, C. et al., Noninvasive tracing of recombinant proteins with “fluorophenylalanine-fingers,” Anal Biochem. Aug. 15, 2000;284(1)29-34. cited by other Miyanohara, A et al., “Expression of hepatitis B surface antigen gene in yeast,” Proc Natl Acad Sci U S A. Jan. 1983;80(1):1-5. cited by other Moore, B. et al., “Quadruplet codons: implications for code expansion and the specification of translation step size,” J. Mol. Biol. 2000; 298(2):195-209. cited by other Mosbach, K. et al., “Formation of proinsulin by immobilized Bacillus subtilis,” Nature Apr. 1983; 302:543-545. cited by other Nakamaye, KL & Eckstein F, “Inhibition of restriction endonuclease Nci I cleavage by phosphorothioate groups and its application to oligonucleotide-directed mutagenesis” Nucleic Acids Res. Dec. 22, 1986;14(24):9679-98. cited by other Nakatsuka, T., et al. “Peptide segment coupling catalyzed by the semisynthetic enzyme thiosubtilisin,” J Am Chem Soc, 1987; 109(12): 3808-3810. cited by other Nambiar, KP et al., “Total synthesis and cloning of a gene coding for the ribonuclease S protein,” Science (1984) 223: 1299-1301. cited by other Needleman, SB and Wunsch CD, “A general method applicable to the search for similarities in the amino acid sequence of two proteins,” J Mol Biol. Mar. 1970;48(3):443-53. cited by other Neet, KE et al. “Properties of thiol-subtilisin. The consequences of converting the active serine residue to cysteine in a serine protease,” J Biol Chem. Dec. 25, 1968;243(24):6392-401. cited by other Nielsen, UB, et al., “Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis,” Biochim Biophys Acta. Aug. 19, 2002:1591(1-3):109-118. cited by other Nomura, T. et al., “Purification, cDNA Cloning, and Expression of UDP-Gal: Glucosylceramide-1,4-Galactosyltransferase from Rat Brain,” J. Biol. Chem. 1998; 273(22):13570-7. cited by other Noren, CJ et al. “A general method for site-specific incorporation of unnatural amino acids into proteins,” Science. Apr. 14, 1989;244(4901):182-8. cited by other Nowak, MW et al., “Nicotinic receptor binding site probed with unnatural amino acid incorporation in intact cells,” Science. Apr. 21, 1995;268(5209):439-42. cited by other Ogawa, AK et al., “Efforts toward the Expansion of the Genetic Alphabet: Information Storage and Replication with Unnatural Hydrophobic Base Pairs,” J. Am. Chem. Soc. 2000; 122(14):3274-3287. cited by other Ogawa, AK et al., “Rational Design of an Unnatural Base Pair with Increased Kinetic Selectivity,” J. Am. Chem. Soc. 2000; 122(36); 8803-8804. cited by other Ohtsuka, E et al., “An alternative approach to deoxyoligonucleotides as hybridization probes by insertion of deoxyinosine at ambiguous codon positions,” J Biol Chem. Mar. 10, 1985;260(5):2605-8. cited by other Olson et al. “Preparation and Characterization of Poly(ethylene glycol)yated Human Growth Hormone Antagonist,” in Poly(ethylene glycol) Chemistry & Biological Applications, 1997; Eds. JM Harris & S. Zalipsky; ACS, Washington, D.C., 170-181. cited by other Padwa, A. “Intermolecular 1,3-Dipolar Cycloadditions,” in Comprehensive Organic Synthesis, vol. 4, (1991) Ed. Trost, B. M.; Pergamon, Oxford, 1069-1109. cited by other Palva, I et al., “Secretion of interferon by Bacillus subtilis,” Gene. May-Jun. 1983;22(2-3):229-35. cited by other Park, JW, et al., “Development of anti-p185HER2 immunoliposomes for cancer therapy,” Proc Natl Acad Sci U S A. Feb. 28, 1995;92(5):1327-31. cited by other Park, JW, et al., “Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery,” Clin Cancer Res. Apr. 2002;8(4):1172-81. cited by other Patnaik, R. and JR Swartz, “E. coli-based in vitro transcription/translation: in vivo-specific synthesis rates and high yields in a batch system,” Biotechniques. May 1998;24(5):862-8. cited by other Pearson, WR and DJ Lipman, “Improved tools for biological sequence comparison,” Proc Natl Acad Sci U S A. Apr. 1988;85(8):2444-8. cited by other Pepinsky, RB., et al., “Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity,” J Pharmacol Exp Ther. Jun. 2001;297(3):1059-66. cited by other Piccirilli, JA et al., “Enzymatic incorporation of a new base pair into DNA and RNA extends the genetic alphabet,” Nature 1990; 343:33-37. cited by other Pintar, A et al. “CX, an algorithm that identifies protruding atoms in proteins,” Bioinformatics. Jul. 2002;18(7):980-4. cited by other Pitha, J et al. “Detergents linked to polysaccharides: preparation and effects on membranes and cells,” Eur J Biochem. Feb. 15, 1979;94(1):11-8. cited by other Polgar, L. and ML Bender. “A new enzyme containing a synthetically formed active site. Thiol-subtilisin.” J. Am Chem Soc., 1966; 88(13): 3153-3154. cited by other Pollack, SJ et al. “Introduction of nucleophiles and spectroscopic probes into antibody combining sites,” Science. Nov. 18, 1988;242(4881):1038-40. cited by other Preneta, AZ. “Separation on the basis of size: gel permeation chromatography,” in Protein Purification Methods, a practical approach, 1989; Eds. Harris & Angal; IRL Press, Oxford; 293-306. cited by other Raibaud, O et M Schwartz. “Positive control of transcription initiation in bacteria,” Annu Rev Genet. 1984;18:173-206. cited by other Reverey, H. et al., “Differential Fatty Acid Selection during Biosynthetic S-Acylation of a Transmembrane Protein (HEF) and Other Proteins in Insect Cells (Sf9) and in Mammalian Cells (CV1),” J. Biol. Chem. 1996; 271 (39):23607-10. cited by other Rivier, J et R McClintock, “Reversed-phase high-performance liquid chromatography of insulins from different species,” J Chromatogr. Sep. 23, 1983;268(1):112-9. cited by other Roberts, et al., “Generation of an antibody with enhanced affinity and specificity for its antigen by protein engineering,” Nature 1987;328:731-734. cited by other Roberts, RW and JW Szostak, “RNA-peptide fusions for the in vitro selection of peptides and proteins,” Proc Natl Acad Sci U S A. Nov. 11, 1997;94(23):12297-302. cited by other Roggenkamp, R. et al., “Transformation of the methylotrophic yeast Hansenula polymorpha by autonomous replication and integration vectors,” Mol. Genetics and Genomics 1986;202(2):302-8. cited by other Romani et al. “Synthesis of unsymmetrical cystine peptides: directed disulfide pairing with the sulfenohydrazide method,” in Chemistry of Peptides and Proteins 1984; eds. Voelter, W. et al.; Walter de Gruyter et al., Berlin; vol. 2:29-33. cited by other Romanos, MA et al., “Foreign gene expression in yeast: a review,” Yeast. Jun. 1992;8(6):423-88. cited by other Rosenthal, GA. “L-canaline: a potent antimetabolite and anti-cancer agent from leguminous plants,” Life Sci.1997;60(19):1635-41. cited by other Rossolini, GM et al., “Use of deoxyinosine-containing primers vs degenerate primers for polymerase chain reaction based on ambiguous sequence information,” Mol. Cell. Probes 1994; 8:91-98. cited by other Rostovtsev, VV et al., “A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective “ligation” of azides and terminal alkynes,” Angew Chem Int Ed Engl Jul. 15, 2002,41(14):2596-9. cited by other Rowles, J et al., “Cloning and characterization of PDK4 on 7q21.3 encoding a fourth pyruvate dehydrogenase kinase isoenzyme in human,” J Biol Chem. Sep. 13, 1996;271(37):22376-82. cited by other Sakmar, TP and Khorana HG, “Total synthesis and expression of a gene for the alpha-subunit of bovine rod outer segment guanine nucleotide-binding protein (transducin)” Nucleic Acids Res. Jul. 25, 1988;16(14A):6361-72. cited by other Sandler and Karo, “Polyoxyalkylation of hydroxyl compounds,” in Polymer Synthesis, vol. 3, 1980; Academic Press, New York, 138-161. cited by other Sartore, L et al., “Enzyme modification by MPEG with an amino acid or peptide as spacer arms,” Appl Biochem Biotechnol. Jan. 1991;27(1):45-54. cited by other Sawhney, AS et al., “Bioerodible Hydrogels Based on Photopolymerized Poly(ethylene glycol)-co-poly(alpha-hydroxy acid) Diacrylate Macromers,” Macromolecules 1993; 26(4):581-7. cited by other Saxon, E and C. Bertozzi, “Cell Surface Engineering by a Modified Staudinger Reaction,” Science (2000); 287 (5460):2007-2010. cited by other Sayers, JR et al., “Strand specific cleavage of phosphorothioate-containing DNA by reaction with restriction endonucleases in the presence of ethidium bromide” Nucleic Acids Res. Feb. 11, 1988;16(3):803-14. cited by other Sayers, JR, et al. “5′-3′ exonucleases in phosphorothioate-based oligonucleotide-directed mutagenesis,” Nucleic Acids Res. Feb. 11, 1988;16(3):791-802. cited by other Schanbacher, FL et al. “Galactosyltransferase Acceptor Specificity of the Lactose Synthetase A Protein,” J. Biol. Chem. 1970; 245(19):5057-5061. cited by other Schmidt, M et al., “Baculovirus-mediated large-scale expression and purification of a polyhistidine-tagged rubella virus capsid protein,” Protein Expr Purif. Apr. 1998;12(3):323-30. cited by other Schneider, E., et al., “Functional Purification of a Bacterial ATP-Binding Cassette Transporter Protein (MaIK) from the Cytoplasmic Fraction of an Overproducing Strain,” Protein Expr. Purif. 1995; 6(1):10-14. cited by other Schnolzer, M. and SBH Kent. “Constructing proteins by dovetailing unprotected synthetic peptides: backbone-engineered HIV protease,” Science. Apr. 10, 1992;256(5054):221-5. cited by other Scouten, WH. “A survey of enzyme coupling techniques,” Methods Enzymol. 1987;135:30-65. cited by other Shao, J and JP Tam, “Unprotected Peptides as Building Blocks for the Synthesis of Peptide Dendrimers with Oxime, Hydrazone, and Thiazolidine Linkages,” J. Am. Chem. Soc. 1995; 117(14):3893-3899. cited by other Sharma, N et al., “Efficient introduction of aryl bromide functionality into proteins in vivo,” FEBS Lett. Feb. 4, 2000;467 (1):37-40. cited by other Shimatake, H et M Rosenberg, “Purified gamma regulatory protein cII positively activates promoters for lysogenic development,” Nature Jul. 1981; 292:128-132. cited by other Shine, J and L Dalgarno, “Determinant of cistron specificity in bacterial ribosomes,” Nature. Mar. 6, 1975;254 (5495):34-8. cited by other Sidman, KR et al., “Controlled release of macromolecules and pharmaceuticals from synthetic polypeptides based on glutamic acid,” Biopolymers. Jan. 1983;22(1):547-56. cited by other Sieber, V. et al., “Libraries of hybrid proteins from distantly related sequences,” Nature Biotechnology, May 2001;19:456-460. cited by other Siffert, W et al., “Association of a human G-protein beta3 subunit variant with hypertension,” Nat Genet. Jan. 1998;18(1):45-8. cited by other Sikorski, RS et al., “A System of Shuttle Vectors and Yeast Host Strains Designed for Efficient Manipulation of DNA in Saccharomyces cerevisiae,” Genetics (1989) 122:19-27. cited by other Sisk, WP et al., “High-level expression and purification of secreted forms of herpes simplex virus type 1 glycoprotein gD synthesized by baculovirus-infected insect cells,” J Virol. Feb. 1994;68(2):766-75. cited by other Sjolander, A et al., “The serum albumin-binding region of streptococcal protein G: a bacterial fusion partner with carrier-related properties,” J Immunol Methods. Feb. 14, 1997;201(1):115-23. cited by other Smith, M. “In vitro mutagenesis” Ann. Rev. Genet. 1985; 19:423-462. cited by other Smith, GE et al., “Production of human beta interferon in insect cells infected with a baculovirus expression vector,” Mol Cell Biol. Dec. 1983;3(12):2156-65. cited by other Stanley, SL et al., “The serine-rich Entamoeba histolytica protein is a phosphorylated membrane protein containing O-linked terminal N-acetylglucosamine residues,” J Biol Chem. Feb. 24, 1995;270(8):4121-6. cited by other Steitz, JA et al. “Genetic signals and nucleotide sequences in messenger RNA,” in Biological Regulation and Development: Gene Expression 1979; ed. R. F. Goldberger; Plenum Press, New York; 349-399. cited by other Stemmer, WPC, “Rapid evolution of a protein in vitro by DNA shuffling,” Nature 1994;370(4):389-391. cited by other Stemmer, WP “DNA shuffling by random fragmentation and reassembly: in vitro recombination for molecular evolution,” Proc Natl Acad Sci U S A. Oct. 25, 1994;91(22):10747-51. cited by other Studier, FW et BA Moffatt, “Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes,” J. Mol Biol. May 5, 1986;189(1):113-30. cited by other Subasinghe, N. et al., “Quisqualic acid analogues: synthesis of beta-heterocyclic 2-aminopropanoic acid derivatives and their activity at a novel quisqualate-sensitized site,” J Med Chem. Nov. 27, 1992;35(24):4602-7. cited by other Switzer, C et al., “Enzymatic incorporation of a new base pair into DNA and RNA,” J. Am. Chem. Soc. 1989; 111 (21):8322-8323. cited by other Tabor, S et CC Richardson, “A bacteriophage T7 RNA polymerase/promoter system for controlled exclusive expression of specific genes,” Proc Natl Acad Sci U S A. Feb. 1985;82(4):1074-8. cited by other Tae, EL et al., “Efforts toward Expansion of the Genetic Alphabet: Replication of DNA with Three Base Pairs,” J. Am. Chem. Soc. 2001; 123(30)7439-7440. cited by other Tang, Y et al., “Fluorinated Coiled-Coil Proteins Prepared In Vivo Display Enhanced Thermal and Chemical Stability,” Angew Chem Int Ed Engl. Apr. 17, 2001;40(8):1494-1496. cited by other Taylor, JW et al., “The use of phosphorothioate-modified DNA in restriction enzyme reactions to prepare nicked DNA,” Nucleic Acids Res. Dec. 20, 1985;13(24):8749-64. cited by other Taylor, JW et al., “The rapid generation of oligonucleotide-directed mutations at high frequency using phosphorothioate-modified DNA,” Nucleic Acids Res. Dec. 20, 1985;13(24):8765-85. cited by other Tijssen, P. “Overview of principles of hybridization and the strategy of nucleic acid assays,” in Laboratory Techniques in Biochemistry and Molecular Biology—Hybridization with Nucleic Probes, Part I, 1993; Elsevier Science Publishers, Amsterdam, 19-78. cited by other Tilburn, J. et al., “Transformation by integration in Aspergillus nidulans,” Gene. Dec. 1983;26(2-3):205-21. cited by other Chang, CN, et al., “High-level secretion of human growth hormone by Escherichia coli” Gene. 1987;55(2-3):189-96. cited by other Deonarain, R et al. “Interferon-alpha/beta-receptor interactions: a complex story unfolding,” Curr Pharm Des. 2002;8 (24):2131-7. cited by other Devlin, JJ et al., “Expression of granulocyte colony-stimulating factor by human cell lines,” J Leukoc Biol. Apr. 1987;41(4):302-6. cited by other Di Marco, S et al., “Mutational analysis of the structure-function relationship in interferon-alpha,” Biochem Biophys Res Commun. Aug. 15, 1994;202(3):1445-51. cited by other Domanski, P. et OR Colamonici. “The type-I interferon receptor. The long and short of it,” Cytokine Growth Factor Rev. Aug. 1996;7(2):143-51. cited by other Durbin, JE, et al. “Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease,” Cell. Feb. 9, 1996;84(3):443-50. cited by other Dusheiko, GM et al. “Recombinant leucocyte interferon treatment of chronic hepatitis B. An analysis of two therapeutic trials,” J Hepatol. 1986;3 Suppl 2:S199-207. cited by other Edge, M.D. et al. “Interferon analogues from synthetic genes: an approach to protein structure-activity studies,” Interferon. 1986;7:1-46. cited by other Evinger, M and S. Pestka, “Assay of growth inhibition in lymphoblastoid cell cultures,” Methods Enzymol. 1981;79(Pt B):362-8. cited by other Fimia, GM et al. “Conventional protein kinase C inhibition prevents alpha interferon-mediated hepatitis C virus replicon clearance by impairing STAT activation,” J Virol. Dec. 2004;78(23):12809-16. cited by other Finter, NB et al. “The use of interferon-alpha in virus infections,” Drugs. Nov. 1991;42(5):749-65. cited by other Forti, RL et al., “Objective antiviral assay of the interferons by computer assisted data collection and analysis,” Methods Enzymol. 1986;119:533-40. cited by other Foser, S. et al. “Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS),” Protein Expr Purif. Jul. 2003;30(1):78-87. cited by other Foser, S. et al. “Improved biological and transcriptional activity of monopegylated interferon-alpha-2a isomers,” Pharmacogenomics J. 2003;3(6):312-9. cited by other Foster, GR. “Review article: pegylated interferons: chemical and clinical differences,” Aliment Pharmacol Ther. Oct. 15, 2004;20(8):825-30. cited by other Fountoulakis, M et al. “Purification and biochemical characterization of a soluble human interferon gamma receptor expressed in Escherichia coli,” J Biol Chem. Aug. 5, 1990;265(22):13268-75. cited by other Fried, MW. “Side effects of therapy of hepatitis C and their management,” Hepatology. Nov. 2002;36(5 Suppl 1): S237-44. cited by other Fried, MW et al. “Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection,” N Engl J Med. Sep. 26, 2002;347(13):975-82. cited by other Geng, X et al. “Refolding and purification of interferon-gamma in industry by hydrophobic interaction chromatography,” J Biotechnol. Sep. 30, 2004;113(1-3):137-49. cited by other Giron-Michel, J. “Direct signal transduction via functional interferon-alphabeta receptors in CD34+ hematopoietic stem cells,” Leukemia. Jun. 2002;16(6):1135-42. cited by other Goeddel, DV et al., “Human leukocyte interferon produced by E. coli is biologically active,” Nature. Oct. 2, 1980;287 (5781):411-6. cited by other Goeddel, DV et al., “The structure of eight distinct cloned human leukocyte interferon cDNAs,” Nature. Mar. 5, 1981;290(5801):20-6. cited by other Gongora, R. et al. “An essential role for Daxx in the inhibition of B lymphopoiesis by type I interferons,” Immunity. Jun. 2001;14(6):727-37. cited by other Grace, M. et al. “Structural and biologic characterization of pegylated recombinant IFN-alpha2b,” J Interferon Cytokine Res. Dec. 2001;21(12):1103-15. cited by other Grace, MJ et al. “Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway,” J Biol Chem. Feb. 25, 2005;280(8):6327-36. Epub Dec. 13, 2004. cited by other Gray, PW et al. “Expression of human immune interferon cDNA in E. coli and monkey cells,” Nature. Feb. 11, 1982;295(5849):503-8. cited by other Gresser, I. “Wherefore interferon?,” J Leukoc Biol. May 1997;61(5):567-74. cited by other Hamilton, JA et al. “Endogenous IFN-alpha beta suppresses colony-stimulating factor (CSF)-1-stimulated macrophage DNA synthesis and mediates inhibitory effects of lipopolysaccharide and TNF-alpha,” J Immunol. Apr. 1, 1996;156(7):2553-7. cited by other Han, CS et al. “Antiviral activities of the soluble extracellular domains of type I interferon receptors,” Proc Natl Acad Sci U S A. May 22, 2001:98(11):6138-43. Epub May 8, 2001. cited by other Harding, L et al. “Stimulation of prostaglandin E2 synthesis by interleukin-1beta is amplified by interferons but inhibited by interleukin-4 in human amnion-derived WISH cells,” Biochim Biophys Acta. Jan. 10, 1996;1310(1):48-52. cited by other Hardy, MP et al. “The soluble murine type I interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both agonistic and antagonistic propertiesm” Blood. Jan. 15, 2001;97(2):473-82. cited by other He, Y et al. “The regulation of hepatitis C virus (HCV) internal ribosome-entry site-mediated translation by HCV replicons and nonstructural proteins,” J Gen Virol. Mar. 2003;84(Pt 3):535-43. cited by other Heidemann, E. et al., English abstract from PubMed for “Improved clinical course of herpes zoster in immunosuppressed patients treated with fibroblast interferon,” Onkologie. Aug. 1984;7(4):210-2. cited by other Henco, K. et al. “Structural relationship of human interferon alpha genes and pseudogenes,” J Mol Biol. Sep. 20, 1985;185(2):227-60. cited by other Hermeling, S. et al. “Structure-immunogenicity relationships of therapeutic proteins,” Pharm Res. Jun. 2004;21 (6):897-903. cited by other Hilkens, CMU et al. “Differential responses to IFN-alpha subtypes in human T cells and dendritic cells,” J Immunol. Nov. 15, 2003;171(10):5255-63. cited by other Hiscott, J et al. “Differential expression of human interferon genes,” Nucleic Acids Res. May 11, 1984;12(9):3727-46. cited by other Hochuli, E. “Large-scale recovery of interferon alpha-2a synthesized in bacteria,” Chimia 1986; 40(11):408-412. cited by other Hu, R. et al. “Human IFN-alpha protein engineering: the amino acid residues at positions 86 and 90 are important for antiproliferative activity,” J Immunol. Aug. 1, 2001;167(3):1482-9. cited by other Hu, R et al. “Divergence of binding, signaling, and biological responses to recombinant human hybrid IFN,” J Immunol. Jul. 15, 1999;163(2):854-60. cited by other Chawla, RK, et al., “Structural variants of human growth hormone: biochemical, genetic, and clinical aspects” Annu Rev Med. 1983;34:519-47. cited by other Chiba, T. et al., “Tryptophan residue of Trp-Ser-X-Trp-Ser motif in extracellular domains of erythropoietin receptor is essential for signal transduction,” Biochim. Biophys. Res. Comm. (1992);184: 485-490. cited by other Cunningham, BC et JA Wells. “High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis,” Science. Jun. 2, 1989;244(4908):1081-5. cited by other Cunningham, BC et al. “Receptor and antibody epitopes in human growth hormone identified by homolog-scanning mutagenesis,” Science. Mar. 10, 1989;243(4896):1330-6. cited by other Cunningham, BC and JA Wells, “Rational design of receptor-specific variants of human growth hormone” Proc Natl Acad Sci U S A. Apr. 15, 1991;88(8):3407-11. cited by other Cunningham, BC, et al., “Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule,” Science. Nov. 8, 1991;254(5033):821-5. cited by other Cunningham, BC et JA Wells. “Comparison of a structural and a functional epitope,” J. Mol Biol. Dec. 5, 1993;234 (3):554-63. cited by other Davis, Set al., “LIFR and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor, ”Science 1993; 260: 1805-1808. cited by other Tondelli, L. et al. “Poly(ethylene Glycol) Imidazolyl Formates as Oligomeric Drug-Binding Matrices,” J. Controlled Release 1985;1(4):251-7. cited by other Tornoe, CW et al., “Peptidotriazoles on solid phase: [1,2,3]-triazoles by regiospecific copper(i)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides,” J Org Chem. May 3, 2002;67(9):3057-64. cited by other Trotter, KM and HA Wood, “Transfection techniques for producing recombinant baculoviruses,” in Methods in Molecular Biology—Baculovirus Expression Protocols, vol. 39 (1995); Ed. C.D. Richardson, 97-107. cited by other Tschumper, G. et al., “Sequence of a yeast DNA fragment containing a chromosomal replicator and the TRP1 gene,” Gene 1980; 10(2):157-66. cited by other Turcatti, G et al. “Probing the structure and function of the tachykinin neurokinin-2 receptor through biosynthetic incorporation of fluorescent amino acids at specific sites,” J Biol Chem. Aug. 16, 1996;271(33):19991-8. cited by other Van Den Berg, JA et al., “Kluyveromyces as a host for heterologous gene expression: expression and secretion of prochymosin,” Biotechnology (N Y). Feb. 1990;8(2):135-9. cited by other Van Hest, JC and DA Tirrell, “Efficient introduction of alkene functionality into proteins in vivo,” FEBS Lett. May 22, 1998;428(1-2):68-70. cited by other Van Hest, J. C. et al., “Efficient Incorporation of Unsaturated Methionine Analogues into Proteins in Vivo,” J. Am. Chem. Soc.2000 ;122 (7); 1282-1288. cited by other Van Solingen, P. et JB van der Plaat. “Fusion of yeast spheroplasts,” J Bacteriol. May 1977;130(2):946-7. cited by other Veronese, FM et al., “Surface modification of proteins. Activation of monomethoxy-polyethylene glycols by phenylchloroformates and modification of ribonuclease and superoxide dismutase,” Appl Biochem Biotechnol. Apr. 1985:11(2):1 41-52. cited by other Vlak, JM et al., “Functional studies on the p10 gene of Autographa californica nuclear polyhedrosis virus using a recombinant expressing a p10-beta-galactosidase fusion gene,” J Gen Virol. Apr. 1988;69 ( Pt 4):765-76. cited by other Wang, Q., et al., “Bioconjugation by Copper(I)-Catalyzed Azide-Alkyne [3+2] Cycloaddition,” J. Am. Chem. Soc. 2003; 125(11):3192-3193. cited by other Wang, L et al., “Addition of the keto functional group to the genetic code of Escherichia coli,” Proc. Natl. Acad. Sci. (2003); 100(1):56-61. cited by other Wang, L et al., “Expanding the genetic code of Escherichia coli,” Science. Apr. 20, 2001;292(5516):498-500. cited by other Wang, L & PG Schultz, “Expanding the genetic code,” Chem Commun (Camb). Jan. 7, 2002;1:1-11. cited by other Weissmann, C. “The cloning of interferon and other mistakes.” in Interferon 3 1981; ed. I. Gresser; Academic Press, London, 101-134. cited by other Wells, JA et al., “Importance of hydrogen-bond formation in stabilizing the transition state of subtilisin,” Phil. Trans. R. Soc. Lond. A 1986; 317: 415-423. cited by other Wells, JA et al., “Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites,” Gene. 1985;34(2-3):315-23. cited by other Woghiren, C et al. “Protected thiol-polyethylene glycol: a new activated polymer for reversible protein modification,” Bioconjug Chem. Sep.-Oct. 1993;4(5):314-8. cited by other Wong, SS et LJ Wong, “Chemical crosslinking and the stabilization of proteins and enzymes,” Enzyme Microb Technol. Nov. 1992;14(11):866-74. cited by other Wright, K. “Biotechnology: Insect virus as super-vector?,” Nature (1986) 321(6072):718. cited by other Yelton, MM et al., “Transformation of Aspergillus nidulans by using a trpC plasmid,” Proc Natl Acad Sci U S A. Mar. 1984;81(5):1470-4. cited by other Yelverton, E et al., “Bacterial synthesis of a novel human leukocyte interferon,” Nucleic Acids Res. Feb. 11, 1981;9 (3):731-41. cited by other Zalipsky, S et al. “Attachment of drugs to polyethylene glycols,” Eur. Polymer Journal. 1983 19(12):1177-83. cited by other Zalipsky, S. “Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates,” Bioconjug Chem. Mar.-Apr. 1995;6(2):150-65. cited by other Zhang, Z., et al. “A new strategy for the site-specific modification of proteins in vivo,” Biochemistry. Jun. 10, 2003;42 (22):6735-46. cited by other Zoller, MJ & M Smith, “Oligonucleotide-directed mutagenesis using M13-derived vectors: an efficient and general procedure for the production of point mutations in any fragment of DNA” Nucleic Acids Res. Oct. 25, 1982;10 (20):6487-500. cited by other Zoller, MJ & M. Smith, “Oligonucleotide-directed mutagenesis of DNA fragments cloned into M13 vectors” Methods Enzymol. 1983;100:468-500. cited by other Wada, M. et al., “The 20-kilodalton (kDa) human growth hormone (hGH) differs from the 22-kDa hGH in the complex formation with cell surface hGH receptor and hGH-binding protein circulating in human plasma,” Mol Endocrinol. Jan. 1998;12(1):146-56. cited by other Walter, MR et al., “Three-dimensional structure of recombinant human granulocyte-macrophage colony-stimulating factor,” J Mol Biol. Apr. 20, 1992;224(4):1075-85. cited by other Wells, JA. “Binding in the growth hormone receptor complex,” Proc Natl Acad Sci U S A. Jan. 9, 1996;93(1):1-6. cited by other Wen, D. et al., “Erythropoietin structure-function relationships. Identification of functionally important domains,” J. Biol. Chem. (1994) 269(36):22839-22846. cited by other Zink, T. et al., “Secondary structure of human granulocyte colony-stimulating factor derived from NMR spectroscopy” FEBS Lett. Dec. 21, 1992;314(3):435-9. cited by other Zink, T. et al., “Structure and dynamics of the human granulocyte colony-stimulating factor determined by NMR spectroscopy. Loop mobility in a four-helix-bundle protein” Biochemistry. Jul. 19, 1994;33(28):8453-63. cited by other Zoller, MJ & Smith M, “Oligonucleotide-directed mutagenesis: a simple method using two oligonucleotide primers and a single-stranded DNA template,” Methods Enzymol. 1987;154:329-50. cited by other Trotta, et al. “Approval Standards for Alfa Interferon Subtypes,” Drug Information Journal 2000; 34:1231-1246. cited by other Caliceti, P et FM Veronese. “Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates,” Adv Drug Deliv Rev. Sep. 26, 2003;55(10):1261-77. cited by other Clark, EDB, “Refolding of recombinant proteins,” Curr Opin Biotechnol Apr. 1, 1998;9(2):157-63. cited by other Clark, EDB, “Protein refolding for industrial processes,” Curr Opin Biotechnol Apr. 2001;12(2):202-7. cited by other Davis, GD et al., “New fusion protein systems designed to give soluble expression in Escherichia coli,” Biotechnol Bioeng Nov. 20, 1999;65(4):382-8. cited by other Duncan, R. “The dawning era of polymer therapeutics,” Nat Rev Drug Discov May 2003;2(5):347-60. cited by other Gaertner, HF et RE Offord. “Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins,” Bioconjug Chem Jan.-Feb. 1996;7(1):38-44. cited by other Gu, Z et al. “Chromatographic methods for the isolation of, and refolding of proteins from, Escherichia coli inclusion bodies,” Protein Expr Purif. Jun. 2002;25(1):174-9. cited by other Hohsaka, T et M Sisido. “Incorporation of non-natural amino acids into proteins,” Curr Opin Chem Biol. Dec. 2002;6 (6):809-15. cited by other Lilie, H et al. “Advances in refolding of proteins produced in E coli,” Curr Opin Biotechnol. Oct. 1998;9(5):497-501. cited by other Tsumoto, K et al. “Practical considerations in refolding proteins from inclusion bodies,” Protein Expr Purif. Mar. 2003;28(1):1-8. cited by other Wang, W. “Instability, stabilization, and formulation of liquid protein pharmaceuticals,” Int J Pharm. Aug. 20, 1999;185 (2):129-88. cited by other Abril, E et al. “Unresponsiveness to interferon associated with STAT1 protein deficiency in a gastric adenocarcinoma cell line,” Cancer Immunol Immunother. Oct. 1998;47(2):113-20. cited by other Allen, JD et al., “Hybrid (BDBB) interferon-alpha: preformulation studies,” International Journal of Pharmaceutics Oct. 5, 1999;187(2):259-72. cited by other Berraondo, P et al., “The woodchuck interferon-alpha system: Cloning, family description, and biologic activity,” J. Med. Virology Nov. 2002;68(3):424-32. cited by other Brem, R et al. “Inhibition of proliferation by 1-8U in interferon-alpha-responsive and non-responsive cell lines,” Cell Mol Life Sci Jun. 2003;60(6):1235-48. cited by other Bukowski, R et al. “Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study,” J Clin Oncol. Sep. 15, 2002;20(18):3841-9. cited by other Capuron, L et al., “Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy,” Am. J. Psychiatry Jul. 2003;160(7):1342-5. cited by other Colamonici, OR et al., “Interferon alpha (IFN alpha) signaling in cells expressing the variant form of the type I IFN receptor,” J. Biol. Chem. Feb. 25, 1994;269(8):5660-5. cited by other Cotler, SJ et al. “Induction of IL-1Ra in resistant and responsive hepatitis C patients following treatment with IFN-con1,” J Interferon Cytokine Res. May 2002;22(5):549-54. cited by other Cotler, SJ et al. “An Analysis of Acute Changes in Interleukin-6 Levels After Treatment of Hepatitis C with Consensus Interferon,” Journal Interferon Cytokine Res Dec. 2001; 21(12): 1011-1019. cited by other Da Silva, AJ et al. “Comparison of gene expression patterns induced by treatment of human umbilical vein endothelial cells with IFN-alpha 2b vs. IFN-beta 1a: understanding the functional relationship between distinct type I interferons that act through a common receptor,” J Interferon Cytokine Res Feb. 2002;22(2):173-88. cited by other De Veer, MJ et al. “Functional classification of interferon-stimulated genes identified using microarrays,” J Leukoc Biol. Jun. 2001;69(6):912-20. cited by other Der SD et al. “Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays,” Proc Natl Acad Sci U S A. Dec. 22, 1998;95(26):15623-8. cited by other Domanski, P et al., “Cloning and expression of a long form of the beta subunit of the interferon alpha beta receptor that is required for signaling,” J. Biol. Chem. Sep. 15, 1995;270(37):21606-11. cited by other Fiebich, BL et al., “Interleukin-1beta induces cyclooxygenase-2 and prostaglandin E(2) synthesis in human neuroblastoma cells: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB,” J Neurochem. Nov. 2000;75(5):2020-8. cited by other Fish, EN et al. “Activation of a CrkL-Stat5 Signaling Complex by Type I Interferons,” J. Biol. Chem. Jan. 1999;274:571-573. cited by other Formann, E et al. “Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1,” J Viral Hepat Jul. 2003;10(4):271-6. cited by other Glue, P et al. “A Dose-Ranging Study of Pegylated Interferon Alfa-2b and Ribavirin in Chronic Hepatitis C,” Hepatology Sep. 2000;32(3):647-653. cited by other Hawkins, MJ et al. “Comparison of the biologic effects of two recombinant human interferons alpha (rA and rD) in humans,” J Clin Oncol Mar. 1984;2(3):221-6. cited by other Honda, S et al. “Escherichia coli-derived human interferon-gamma with Cys-Tyr-Cys at the N-terminus is partially N alpha-acylated,” Arch Biochem Biophys. Mar. 1989;269(2):612-22. cited by other Hoozemans, JJ et al., “Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain,” Acta Neuropathol (Berl.) Jan. 2001;101(1):2-8. cited by other Hoozemans, JJ et al., “Interleukin-1beta induced cyclooxygenase 2 expression and prostaglandin E2 secretion by human neuroblastoma cells: implications for Alzheimer's disease,” Exp. Gerontol. Mar. 2001; 36(3):559-70. cited by other Horisberger, MA et S Di Marco., “Interferon-alpha hybrids,” Pharmacol Ther. Jun. 1995;66(3):507-34. cited by other Huang, SF et al. “Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel,” Cancer Res. Oct. 15, 2002;62(20):5720-6. cited by other Ilan, E et al., “The hepatitis C virus (HCV)-Trimera mouse: a model for evaluation of agents against HCV,” J Infect Dis. Jan. 15, 2002;185(2):153-61. Epub Jan. 3, 2002. cited by other Jonasch, E et FG Haluska. “Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities,” Oncologist 2001; 6(1):34-55. cited by other Kim, DK et al. “Comparison of Hematopoietic Activities of Human Bone Marrow and Umbilical Cord Blood CD34 Positive and Negative Cells,” Stem Cells 1999; 17:286-294. cited by other Lamb, MW et NE Martin. “Weight-based versus fixed dosing of peginterferon (40kDa) alfa-2a,” Ann Pharmacother May 2002;36(5):933-5. cited by other Lekmine, F et al. “The CrkL adapter protein is required for type I interferon-dependent gene transcription and activation of the small G-protein Rap1,” Biochem Biophys Res Commun Mar. 8, 2002;291(4):744-50. cited by other Motzer, RJ et al. “Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma,” J Clin Oncol. Mar. 1, 2001;19(5):1312-9. cited by other Murashima, S et al. “Effect of interferon treatment on serum 2′,5′-oligoadenylate synthetase levels in hepatitis C-infected patients,” J Med Virol. Oct. 2000;62(2):185-90. cited by other Novick, D et al. “The human interferon alpha/beta receptor: characterization and molecular cloning,” Cell May 6, 1994;77(3):391-400. cited by other Park, C et al. “Immune Response in Stat2 Knockout Mice,” Immunity Dec. 2000;13(6):795-804. cited by other Peled, A et al. “Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4,” Science Feb. 5, 1999;283(5403):845-8. cited by other Pessina, A et al. “Prevalidation of a model for predicting acute neutropenia by colony forming unit granulocyte/macrophage (CFU-GM) assay,” Toxicol In Vitro Dec. 2001;15(6):729-40. cited by other Rossmann et al., “Expression and purification of recombinant, glycosylated human interferon alpha 2b in Murine myeloma Nso cells”, Protein Expression and Purification, 1996 7:335-342. . cited by other Pessina, A et al. “Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics,” Toxicol Sci. Oct. 2003;75(2):355-67. Epub Jul. 25, 2003. cited by other Purcell, RH. “Hepatitis C virus: historical perspective and current concepts,” FEMS Microbiol Rev Jul. 1994;14 (3):181-91. cited by other Quan, S et al. “Human CD34+ hematopoietic cells transduced by retrovirus-mediated interferon alpha gene maintains regeneration capacity and engraftment in NOD/SCID in mice,” Exp Hematol Oct. 27, 1999(10):1511-8. cited by other Reddy, KR. “Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD),” Semin Liver Dis. 2004;24 Suppl 2:33-8. cited by other Ruiz, L et al. “Long-term stabilization of recombinant human interferon alpha 2b in aqueous solution without serum albumin,” Int J Pharm Oct. 2, 2003;264(1-2):57-72. cited by other Salucci, V et al “Expression of a new woodchuck IFN-alpha gene by a helper-dependent adenoviral vector in woodchuck hepatitis virus-infected primary hepatocytes,” J Interferon Cytokine Res. Oct. 2002;22(910):1027-34. cited by other Samuel, CE. “Antiviral actions of interferons,” Clin Microbiol Rev. Oct. 2001;14(4):778-809. cited by other Saphier, D et al. “Inhibition of neural and neuroendocrine activity by alpha-interferon: neuroendocrine, electrophysiological, and biochemical studies in the rat,” Brain Behav Immun Mar. 1994:8(1):37-56. cited by other Schvvende, H et al. “Differences in the state of differentiation of THP-1 cells induced by phorbol ester and 1,25-dihydroxyvitamin D3”, J Leukoc Biol 1996; 59(4)555-61. cited by other Soza, A. et al. “Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C,” Hepatology. Nov. 2002;36(5):1273-9. cited by other Swaminathan S et N. Khanna. “Affinity purification of recombinant interferon-alpha on a mimetic ligand adsorbent,” Protein Expr Purif Mar. 1999;15(2):236-42. cited by other Takahashi, I et al. “A new IFN-like cytokine, limitin, modulates the immune response without influencing thymocyte development,” J Immunol Sep. 15, 2001;167(6):3156-63. cited by other Tedjarati, S et al. “Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biolobical dose of pegylated interferon alpha combined with paclitaxel,” Clin Cancer Res. Jul. 2002;8 (7):2413-22. cited by other Travers, H et J Girdlestone. “IFN-alpha super-induction of HLA class I expression by a variant thymoma cell line involves nuclear translocation of Rel complexes,” Eur J Immunol. Nov. 1998;28(11):3792-9. cited by other Uddin S et al. “Role of Stat5 in type I interferon-signaling and transcriptional regulation,” Biochem Biophys Res Commun. Aug. 22, 2003;308(2):325-30. cited by other Uno, K et al. “A bioassay for serum interferon based on induction of 2′5′-oligoadenylate synthetase activity,” J Interferon Cytokine Res. Dec. 1998;18(12):1011-8. cited by other Uze, G et al. “Genetic transfer of a functional human interferon alpha receptor into mouse cells: cloning and expression of its cDNA,” Cell Jan. 26, 1990;60(2):225-34. cited by other Voss, T et al. “Periplasmic expression of human interferon-alpha 2c in Escherichia coli results in a correctly folded molecule,” Biochem J. Mar. 15, 1994;298 Pt 3:719-25. cited by other Vyas, K et al. “Biologic activity of polyethylene glycol12000-interferon-alpha2b compared with interferon-alpha2b: gene modulatory and antigrowth effects in tumor cells.” J Immunother. May-Jun. 2003;26(3):202-11. cited by other Wan, L et TW Chang. “Site-specific lipophilic modification of interferon-alpha,” J Protein Chem. Aug. 2002,21 (6):371-81. cited by other Webb, SD et al. “A new mechanism for decreasing aggregation of recombinant human interferon-gamma by a surfactant: Slowed dissolution of lyophilized formulations in a solution containing 0.03% polysorbate 20,” J Pharmaceut Sci Feb. 2002; 91(2):543-558. cited by other Yamano, M. et al. “Corticotropin-releasing hormone receptors mediate consensus interferon-alpha YM643-induced depression-like behavior in mice,” J Pharrnacoi Exp Ther Jan. 2000; 292(1):181-7. cited by other Zawada, WM et al. “Naloxone differentially alters fevers induced by cytokines,” Neurochem Int Apr.-May 1997;30 (4-5):441-8. cited by other Zeuzem, S et al. “Pharmacokinetics of peginterferons,” Semin Liver Dis. 2003;23 Suppl 1:23-8. cited by other |
| Assistant Examiner: | Seharaseyon, Jegatheesan |
| Primary Examiner: | Saoud, Christine J |
| Attorney, Agent or Firm: | Walen, III, John W. Eaton, Kristin S. |
| رقم الانضمام: | edspgr.08097702 |
| قاعدة البيانات: | USPTO Patent Grants |
| الوصف غير متاح. |